American Heart Association Preview 2017.Pdf

NovemberNovember 11-15 11-15 Anaheim,Anaheim, California California

PREVIEWTHE IN CLASS CARDIOVASCULAR CONFERENCE

EDUCATIONAL SESSIONS FOR ALL CAREER STAGES

WITH GLOBAL THOUGHT LEADERS innovative

FACULTY PROVIDING INTERACTIVE, network

PERSONALIZED EDUCATION world- renowned PAID ADVERTISEMENT PICK UP A FREE COPY AT: AHA HeartQuarters, booth #355 Wolters Kluwer, booth #439 Wiley, booth #545 FIND THE ENTIRE AHA /ASA JOURNALS’ TREND WATCH COLLECTION ONLINE

DOWNLOAD ALL 3 ISSUES TODAY!

Freely 450+ Available Articles

INTERACTIVE MAGAZINE

DOWNLOAD THE BLIPPAR APP App required for free, full-text Download the latest issue and view access to Trend Watch. a video demonstration at

AVAILABLE ON www.ahajournals.org/site/trendwatch American Heart Association

American Heart Association National Center 7272 Greenville Ave. Dallas, TX 75231 214-373-6300 800-242-2453 professional.heart.org

Registration INSIDE Convention Data Services 107 Waterhouse Road THE PREVIEW Bourne, MA 02532 800-748-3583 (inside U.S.) 508-743-8517 (outside U.S.) Join the [email protected] AHA Scientific Sessions 2017 conversation Housing 2 Welcome from the program chair onPeak 4 What’s hot at AHA Scientific Sessions 2017 381 Park Ave. S., Third Floor 6 Expect the best in 2017 New York, NY 10 Week at a glance facebook.com/ 800-221-3531 (inside U.S.) ahameetings 312-527-7300 (outside U.S.) [email protected] Advance programming and faculty Facility Anaheim Convention Center 14 Programming information and schedule @AHAmeetings 800 W. Katella Ave. #AHA17 Anaheim, CA 92802 14 CE/CME credit 714-765-8950 20 Meet the faculty

Ascend Integrated Media YouTube 7171 W. 95th St., Suite 300 youtube.com/user/ Overland Park, KS 66212 Science & Technology Hall/ AHASessions 913-469-1110 ascendintegratedmedia.com Unofficial Satellite Events 28 Exhibitors scientificsessions.org 29 Cardiovascular Expert Theater schedule Google+ plus.google.com/ The official American Heart 30 Unofficial Satellite Events schedule +AmericanHeart Association Conference Preview is published by AHA as an exclusive Networking service to AHA Scientific Sessions for Professionals 2017 attendees. While every effort networking. is made to ensure accuracy, AHA Anaheim americanheart.org makes no warranties, expressed or implied, related to the information. 31 The Heartbeat of California Information contained herein is 32 Travel-easy apps subject to change without notice. No part of this publication may be reproduced, stored or transmitted without written permission from AHA.

scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 1 TO Dear Colleagues:

AHA SCIENTIFIC t is my pleasure to invite you to attend AHA Scientific Sessions 2017 in Anaheim, CA. The SESSIONS 2017 American Heart Association’s annual meeting offers an unparalleled opportunity to network with and learn from the preeminent leaders in cardiovascular and stroke science and clinical I practice. This annual event features many opportunities to network with colleagues from around the world in an exciting environment. The scope and quality of the scientific exchange makes Scientific Sessions the premier cardiovascular research and instructional meeting in the world. This events features five days of the best in cardiovascular clinical practice and scientific content covering all aspects of basic, clinical, population and translational content. Scientific Sessions is the American Heart Association’s largest meeting of the year and features: • Exciting Late Breaking Science that will feature the latest breakthroughs in patient care • The first presentation of the 2017 Hypertension Clinical Practice Guidelines • A global health symposium celebrating the 50th anniversary of the Fogarty International Center • Exciting Health Tech sessions featuring leaders in the digital health arena • Dedicated programming on precision medicine during the Precision Medicine Summit • 27 communities covering cardiovascular basic, clinical and population science • 5,000 sessions including thought-provoking Main Event programming and 4,000 WELCOME abstracts • Interactive learning opportunities through the Simulation Zone, Rapid Fire Abstract Sessions and the Genomics Boot Camp Scientific Sessions is at the very forefront of the American Heart Association’s mission to build healthier lives free of cardiovascular disease, and leads the world in innovative learning opportunities for attendees through unprecedented exposure to key thought leaders. For these reasons and many more, I hope you’ll join me this November in Anaheim.

Sincerely yours,

Eric Peterson, MD, MPH, FAHA Chair, Committee on Scientific Sessions Program

2 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org

WHAT’SAT HOT SESSIONSIN 2017

NEW HYPERTENSION GUIDELINES TO BE RELEASED AT AHA SCIENTIFIC SESSIONS Monday, Nov. 13, will feature a full day of programming on the release and implications of the new 2017 Hypertension Clinical Practice Guidelines. The guidelines are anticipated to provide clinicians with new recommendations that will change the FRONTIERS IN SCIENCE SUMMITS way practitioners evaluate and manage high The one-day Frontiers in Science summits highlight the latest, cutting-edge pre-publication blood pressure. research and are designed to maximize informal networking among participants.

FOGARTY The session format consists of rapid-fire pre-publication presentations followed by rich 50TH ANNIVERSARY discussions where attendees can debate the ideas presented to foster dynamic, scientific exchange. It is these interactions that will help push the frontiers of science in each field forward. CELEBRATION The Fogarty International Center at National Frontiers in Science schedule Institutes of Health celebrates a rich and • Arrhythmia Research Summit • Thrombosis Summit varied legacy since its establishment in 1968. Monday, Nov. 13...... 9 a.m.-7 p.m. Monday, Nov. 13...... 9 a.m.-6:45p.m. Join us as we showcase both ongoing and • Stem Cells Summit • Vascular Disease Summit future programs at the center that promote Tuesday, Nov. 14...... 9 a.m.-7 p.m. Tuesday, Nov. 14...... 3:45-7 p.m. the global health agenda and encourage young academics to pursue global health HEALTH TECH SUMMIT research in their own specialties. At the Health Tech Summit — held from 9 a.m. to 6 p.m. on Monday, Nov. 13 — Silicon Valley’s foremost leaders in health technology will share the latest trends and the future of digital In recognition of its 50th year, the Fogarty healthcare solutions and health IT. Speakers include Sue Siegel, GE Ventures; Dennis Schmuland, Symposium will showcase the broad reach MD, Microsoft; James Mault, MD, Qualcomm Life; Jessica Mega, MD, MPH, Verily; and more. of Fogarty-supported research and training in three sessions, and will conclude with a networking event.

4 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org WHAT’S Basic Science Population HOT Basic Science programming provides Population programming explores the most state-of-the-art insights into the underlying effective population-based approaches to mechanisms of cardiovascular development preventing cardiovascular diseases and and disease. These insights ultimately improving cardiovascular health across COMMUNITIEScould lead to the development of effective populations. interventions to better diagnose, treat and prevent cardiovascular disease. Communities

Communities • Lifestyle and Behavioral Medicine • Cardiometabolic Health and Diabetes New name, • Arteriosclerosis, Thrombosis, Vascular • Epidemiology, Big Data, and Precision Biology Medicine same incredible • Cardiac Development, Structure and • Health Tech Function • Prevention Health & Wellness programming • Cellular Biology • Quality of Care • Drug Discovery • Women and Special Populations • Genetics and Genomics Programming Communities • Metabolism and Physiology (formerly known as • Signaling Programming Tracks) Clinical continue to reflect the evolution of scientific Clinical programming delivers access to the latest clinical and scientific applications in the investigation and practice. diagnosis, medical management, prevention and treatment of cardiovascular disease. Hone in on the advanced

learning you need. All Communities

programming communities • Acute Coronary Syndromes • Clinical Trialists are divided into three • Congenital Heart Disease and Pediatric science types: Basic, Cardiology • Electrophysiology and Arrhythmias Clinical and Population. • Heart Failure and Cardiomyopathies • Hypertension and Nephrology • Imaging and Nuclear Medicine • Interventional Treatments • Nursing Research and Clinical and Cardiovascular Clinical Nursing Symposium • Resuscitation Science Symposium • Stroke and Neuroscience • Surgery and Anesthesia • Vascular Disease and Thrombosis

scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 5 EXPECT THE BEST

AHA’s Scientific Sessions 2017 is the blueprint to the future of cardiovascular science and medicine, and is an integral part of the American Heart Association’s mission to build healthier lives, free of cardiovascular disease and stroke. Join us Nov. 11-15 in Anaheim, CA, and expect the best education, networking and conference experience from the premier cardiovascular meeting.

6 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org THE BEST exchange information in this venue located Simulation Zone COLLABORATION in the Science & Technology Hall. Head to this interactive training area in the Science & Technology Hall during Sharing and discussing ideas is at the heart Interventional Central scheduled sessions or at your convenience of AHA Scientific Sessions 2017. Don’t Interventionalists can relax and network to test your cardiac knowledge, skills and miss your opportunity to learn from your in this lounge in the Science & Technology critical thinking. peers during the following events. Hall. You also can take part in career development discussions and educational Body Interact is a screen-based 3-D Early Career Day programming, including: immersive training platform that Taking place on the first day of the meeting, • Global game show virtualizes acute and chronic medical Early Career Day is the perfect occasion • Challenging cases conditions with a lifelike virtual patient. for early career members to network with • Career development topics The simulation includes dynamic senior investigators. The day of learning monitoring, dialoguing, diagnostic tests, includes an opening general session, a Lounges medications, imaging, intervention options networking lunch and specialty breakout Find all of the networking lounges in and performance debriefing. sessions. Throughout the day, you can meet Hall D — the perfect places to relax and experts in the Early Career Engagement meet others with shared interests. Cardiovascular Interventional Lounge — in addition to learning more • FAHA Lounge Simulation is new to the Simulation about the benefits of AHA membership and • Early Career Lounge Zone for 2017. Multiple sessions will collaborating with peers. Wrap up the day • Institute of Precision Medicine Lounge focus on basic through advanced skills with the Early Career Reception. Held in the in the areas of coronary interventional, Early Career Lounge, you can gain insights electrophysiology, valvular heart disease and be inspired by senior clinicians and THE BEST and peripheral artery disease. You will investigators. Starts at 5 p.m. INTERACTIVE have the opportunity to practice a wide range of procedures under the guidance Celebrating Basic Science PROGRAMMING of expert clinicians, plus have hands-on Reception experience using various interventional Network with colleagues at this reception Late-Breaking Science equipment such as guidewires, diagnostic in the Science & Technology Hall, which Get face time with the leading experts in catheters, transcatheter heart valves, pacing recognizes the best of basic science the cardiovascular field as they unveil the electrodes, balloons and stents. abstracts as well as late-breaking basic latest breakthroughs in clinical science. science abstracts. Join us from 11 a.m. These innovative presentations will have a to 1 p.m. on Sunday, Nov. 12, in the Basic significant impact on your clinical practice, Science Poster Area (Booth 2741). making them must-see forums at Scientific Sessions. EP Central Electrophysiologists and others interested AHA Scientific in EP can gather, network, learn and Sessions is: ● The most highly anticipated global exchange forum for cardiovascular scientists and clinicians ● A learning venue where cutting- edge science and clinical practices are discussed and debated ● Known for world-renowned faculty providing interactive, personalized education ● The premier stage for the latest discoveries, translations and applications in basic science, clinical care and population research ● Designed to assist you in improving patient care and outcomes every step of the way.

scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 7 Hemodynamic Simulation is the new name cutting-edge clinical information for for the Mechanical Circulatory Support Advanced Practice Nurses and staff nurses Simulation, which will be available for who care for patients with cardiovascular November 11-15 a third consecutive year. These sessions disease and stroke. The symposium will share Anaheim, California feature a total artificial heart mock proven best clinical practices in the care circulatory loop that provides a hands-on of this patient population. Topics include: opportunity to model critical scenarios precision medicine and pharmacogenetics as and observe hemodynamic consequences. it applies to nursing, the cardiotoxic effects of Both adult and pediatric sessions will be recreational drugs and the underutilization of offered and will include scenarios such as cardiac rehabilitation. inadequate preload/afterload conditions, chronic heart failure and shock and device Resuscitation Science obstruction. Watch for these sessions in Symposium (ReSS) DOWNLOAD THE AHA Room 206B at the convention center. Nov. 11-13 SCIENTIFIC SESSIONS 2017 The 2017 Resuscitation Science Symposium SimMan Vascular, new Simulation Zone (ReSS) is a three-day international forum MOBILE APP TO: for 2017, incorporates a full team training at Scientific Sessions where resuscitation environment from the onset of acute event clinicians and researchers can participate in • View a fully interactive through recovery. During this immersive lively discussion on recent advances related Science & Technology Hall simulation, you will witness a variety of to treating cardiopulmonary arrest and life- floor plan invasive skills while focusing on critical threatening traumatic injury. time management, decision-making and • Schedule sessions communication. With an increasing understanding of the and meetings shared pathophysiology between cardiac Precision Medicine Summit arrest and traumatic injury at multiple levels • Network with attendees Nov. 14 of biological organization, ReSS can provide Clinicians who attend this day-long a unique opportunity for transdisciplinary • Explore the exhibitors program will look at disease prevention and interactions that rapidly translate advances in individualized care. Participants will explore the resuscitation field from fundamental to • Find Anaheim attractions sessions covering big data initiatives, rapid- translational to clinical to population science. fire reports from cardiovascular, genomic and precision medicine leaders and the use Genomics Boot Camp • Receive in-app social AMP UP of precision medicine in the diagnosis and Clinicians and nonscientists will learn the media updates and news your Scienti c Sessions experience treatment of cardiomyopathies. Also, an basic principles of genetics and genomics about AHA Scientific Sessions integrated team of clinical providers will and how those principles are being give a special patient presentation. applied to the practice of medicine. More can’t-miss opportunities Available in the App Store and • EP Central • Posters integrated throughout Cardiovascular Nursing Note: All Genomics Boot Camp participants must Google Play by searching for • Interventional Central the Science & Technology Hall Clinical Symposium complete the Basic Concepts in Genetics and “AHA Events.” This year’s • HealthTech Competition • Engage with more than Nov. 13-14 Genomics CME/CE activity on learn.heart.org conference app will be available The Cardiovascular Nursing Clinical prior to the event. A certificate of completion must in late October. • Simulation Zone 200 exhibitors Symposium is a forum designed to provide be presented for entry. • Meet the Trialist • Hands-Only CPR training • Complimentary coffee breaks • AHA Bistro • Lunch in Cardiovascular • Complimentary professional FIRST TIME ATTENDING Expert Theaters photos taken AHA SCIENTIFIC SESSIONS? • AHA HeartQuarters • WIFI-Charging Lounge Here are a few tips to help you make the most of your time at the meeting.

• Set up a personalized itinerary using • Download the mobile app — and the Online Program Planner. take it with you everywhere. Let it be • Know your goals and choose your guide during Scientific Sessions. sessions that pertain to them. • Join the AHA. You’ll have access to • Build connections to either foster online journals, professional councils, SCIENCE & TECHNOLOGY HALL HOURS | Nov. 12: 11 a.m.–5 p.m. | Nov. 13: 10 a.m.–4:30 p.m. | Nov. 14: 10 a.m.– 3 p.m. a future career or meet others who knowledge transfer, networking share in your specialty. opportunities and more.

8 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org November 11-15 Anaheim, California

AMP UP your Scienti c Sessions experience

More can’t-miss opportunities • EP Central • Posters integrated throughout • Interventional Central the Science & Technology Hall • HealthTech Competition • Engage with more than • Simulation Zone 200 exhibitors • Meet the Trialist • Hands-Only CPR training • Complimentary coffee breaks • AHA Bistro • Lunch in Cardiovascular • Complimentary professional Expert Theaters photos taken • AHA HeartQuarters • WIFI-Charging Lounge

SCIENCE & TECHNOLOGY HALL HOURS | Nov. 12: 11 a.m.–5 p.m. | Nov. 13: 10 a.m.–4:30 p.m. | Nov. 14: 10 a.m.– 3 p.m. THE WEEK AT A GLANCE

8:00 9:00 10:00 11:00 12:00 1:00 2:00

Nov Early Career Day 11 Includes a general session, specialty breakouts and a reception for all. Saturday

Lunch Break Invited Sessions Opening Science & Technology Exhibit Hall Session Nov

Poster Sessions 12 Sunday

Science & Technology Exhibit Hall

Late-Breaking Science Late-Breaking Science Late-Breaking Science Invited Sessions and Invited Sessions and Invited Sessions and Invited Sessions y Lunch Break Science & Technology Exhibit Hall Nov Oral Abstracts Oral Abstracts Oral Abstracts

Poster Sessions

13 ar Red Da We Science & Technology Exhibit Hall

Late-Breaking Science Invited Sessions Invited Sessions and Invited Sessions Lunch Break Science & Technology Exhibit Hall Nov Oral Abstracts Oral Abstracts Oral Abstracts

14 Poster Sessions

ear Sneakers Day Science & Technology Exhibit Hall W

y Clinical Science Late-Breaking Science Nov Trending Topics

15 dnesda Basic Science Population Trending Topics

We Trending Topics

10 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org Don’t Miss These Other Key Events

2:00 3:00 4:00 5:00 6:00 Sa Su M Resuscitation Science Symposium (ReSS) Early Career Day Saturday-Monday Nov. 11-13 Includes a general session, specialty breakouts and a reception for all. M Frontiers in Science: Arrhythmia Research Summit Late-Breaking Science Invited Sessions and Invited Sessions Monday Nov. 13

Oral Abstracts Oral Abstracts M

Poster Sessions Frontiers in Science: Thrombosis Summit Monday Nov. 13 Science & Technology Exhibit Hall M

Late-Breaking Science Late-Breaking Science Health Tech Invited Sessions and Invited Sessions and Invited Sessions Monday Nov. 13

Oral Abstracts Oral Abstracts Oral Abstracts M Tu Poster Sessions Clinical Nursing Symposium Monday-Tuesday Nov. 13-14 Science & Technology Exhibit Hall

Tu Late-Breaking Science Invited Sessions Invited Sessions Lunch Break and Invited Sessions Fogarty Symposium Science & Technology Exhibit Hall Tuesday Nov. 14 Oral Abstracts Oral Abstracts Oral Abstracts

Tu Poster Sessions Frontiers in Science: Stem Cells Summit Science & Technology Exhibit Hall Tuesday Nov. 14

Tu Frontiers in Science: Vascular Disease Summit Tuesday Nov. 14

Tu Clinical Trialists Tuesday Nov. 14

scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 11 2017 Hypertension

Clinical Practice

Guidelines

will be released at AHA Scientific Sessions November 11-15 | Anaheim, California

The 2017 Hypertension Clinical Practice Guidelines will provide clinicians with a series of recommendations that will change the way practitioners evaluate and manage high blood pressure. Hear about it first at AHA Scientific Sessions 2017.

Take advantage of our one-day program and one-day registration rates!

For more information and to register go to Monday, November 13 ScientificSessions.org

10:45 AM Latest Insights into Hypertension Management featuring the Chinese BP Trial, SPRINT Trial, and GATEWAY Trial 2:00 PM 2017 Hypertension Clinical Practice Guidelines

3:45 PM Target: BP™ 2017 Update and Lessons Learned from Participating Practices

5:15 PM Clinical Practice Guidelines for Blood Pressure Management: Next Steps

#AHA17

IVIE-86719_Ascend_Oct_R2.indd 1 9/15/17 2:36 PM Health Tech Summit Technology & Healthcare: The Road Ahead Monday, November 13 | 9 a.m. - 6 p.m. | Anaheim, California Keynote Speakers Sue Siegel Dennis Schmuland, MD James Malt, MD Jessica Mega, MD, MPH

Sessions Disruptive Solutions: Artificial Intelligence Technology Pull vs Push: A Focus on Unmet Needs (Panel Discussion) Health Tech Competition Best Abstracts: Health Tech Digital Health Industry: Hype or Real? ...And More!

One-day rate available! Go to scientificsessions.org to register. #AHA17

IVIE-86719_Ascend_Oct_R2.indd 2 9/15/17 2:36 PM FIVEPACKED DAYS WITH LEARNING

SATURDAY, 10:30-11:45 a.m. INTERVENTIONAL CENTRAL Best Oral Abstract Presentations NOV. 11 and Presentation of the Best Abstract 11-11:45 a.m. Awards for Cardiac and Trauma OMG: What Was I Thinking and Resuscitation Science How Do I Get Out of This? EARLY CAREER Community: Imaging and Nuclear Medicine 2:45-4 p.m. 9 a.m.-Noon Main Event: Prognostication Noon-12:45 p.m. Early Career Opening General After Resuscitation Global Game Show Session: Transitions Community: Interventional Treatments

9 a.m.-5:45 p.m. SUNDAY, 3:30-4:30 p.m. PVD Workshops Case-Based Vascular NOV. 12 Intervention 1-3 p.m. Community: Imaging and Nuclear Medicine Early Career breakout sessions EP CENTRAL 5-6:30 p.m. LATE-BREAKING SCIENCE Early Career reception 11:15 a.m.-12:30 p.m. Jeopardy Game I 3:45-5 p.m. Community: Electrophysiology and Arrhythmias CABG and EP Peri-procedural RESUSCITATION SCIENCE Dilemmas SYMPOSIUM (ReSS) 3:15-4:30 p.m. Electrophysiology and Arrhythmias Jeopardy Game II 8:15-9:30 a.m. Community: Electrophysiology and Arrhythmias Main Event: Outcomes of Cardiac MAIN EVENT SESSION Arrest Survivors With ICDs GENETICS AND GENOMICS 3:45-5 p.m. 9:30-10:15 a.m. Curing Atrial Fibrillation: Awards for Lifetime Achievement 8 a.m.-Noon Where to Next? in Cardiac Resuscitation Science Clinical Genomics Boot Camp Electrophysiology and Arrhythmias and Trauma Resuscitation Science and Presentation of the Ian G. Jacobs Award for International OPENING SESSION Group Collaboration to Advance Resuscitation Science 1-3 p.m. Opening Session Cross Specialty To claim credits, stop by the Communication Center, click the “Claim CE/CME CME” icon in the Mobile Meeting Guide app or visit learn.heart.org. Credit must be claimed within 30 days of the conference.

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 14 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. RESUSCITATION SCIENCE 3:45-4:15 p.m. EP CENTRAL SYMPOSIUM (ReSS) Cardiovascular Interventional: Coronary Intervention Simulation: 11 a.m.-Noon 9:30-10:30 a.m. Core Angiography Skills Meet the Editors of Circulation: Main Event: Year in Review Community: Interventional Treatments Arrhythmia and Electrophysiology Community: Electrophysiology and Arrhythmias 10:45-11:45 a.m. 4:15-4:45 p.m. Oral Abstracts – Basic Science/ Cardiovascular Interventional: Translational Valvular Heart Disease Simulation: FRONTIERS IN SCIENCE: TAVR II ARRHYTHMIA RESEARCH 10:45-11:45 a.m. Community: Interventional Treatments SUMMIT Oral Abstracts – Clinical RESS Community: Electrophysiology and Arrhythmias 4:15-5 p.m. Noon-1:15 p.m. SimMan Vascular: Simulation 2 9-10:30 a.m. Main Event: The Role of Genetics Community: Interventional Treatments Innovations in Therapy for Ventricular in Cardiac Arrest and Trauma Arrhythmogenesis

3:15-4:15 p.m. SUNDAY MORNING 10:45 a.m.-12:15 p.m. Oral Abstracts – Cardiac Arrest PROGRAM Triggers, Remodeling and Stressors Epidemiology Community: Cross Specialty 1:15-2:45 p.m. 3:15-4:15 p.m. 8-11 a.m. Intervening on the System to Improve Oral Abstracts – Trauma Groundbreaking Studies in the Care of Patients With Arrhythmia Practice of Cardiovascular Medicine: 4:30-5:45 p.m. Circulation Editors’ Choices 3-4:30 p.m. Main Event: New Directions Better Design for Arrhythmia in Dispatch-Assisted CPR 8-11 a.m. Prevention and Treatment The Best of Circulation Research Symposium 4:45-6:15 p.m. SIMULATION ZONE Targeting Atrial Fibrillation 11:15-11:45 a.m. MONDAY, Cardiovascular Interventional: FRONTIERS IN SCIENCE: Valvular Heart Disease Simulation: NOV. 13 THROMBOSIS SUMMIT TAVR I Community: Arteriosclerosis, Thrombosis, Community: Interventional Treatments Vascular Biology CARDIOVASCULAR 11:45 a.m.-12:15 p.m. NURSING CLINICAL 9-10:15 a.m. Cardiovascular Interventional: SYMPOSIUM Aggressive Thrombosis Syndromes Cardiac Electrophysiology Simulation: 1 p.m. Atrial Fibrillation Ablation Opening remarks 10:45 a.m.-Noon Community: Electrophysiology and Arrhythmias Inflammation and Thrombosis 1:10 p.m. 12:15-12:45 p.m. Session 1: Precision Medicine 2-3:15 p.m. Body Interact: Heart Failure Sol Sherry Distinguished Lecture Community: Heart Failure and Cardiomyopathies 2 p.m. in Thrombosis Session 2: Pharmacogenomics 12:15-1 p.m. in Clinical Practice 3:45-5 p.m. SimMan Vascular: Simulation 1 New and Emerging Anticoagulant Community: Interventional Treatments 3 p.m. Drugs Session 3: Panel Discussion – 3:15-3:45 p.m. Updates in Interventional Cardiology 5:30-6:45 p.m. Body Interact: Pulmonary Embolism: Biology, Peripheral Artery Disease Prevention and Intervention Community: Vascular Disease and Thrombosis

Data current as of Sept. 5. scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 15 Continued from page 15 LATE-BREAKING SCIENCE RESUSCITATION SCIENCE SYMPOSIUM (ReSS) 9-10:15 a.m. 9:30-10:45 a.m. HEALTH TECH SUMMIT Late-Breaking Science in Prevention Main Event: Educational Innovations Community: Health Tech Prevention, Health and Wellness in Resuscitation

9-10:15 a.m. 10:45 a.m.-Noon 10:45-11:45 a.m. Technology and Health Care: Latest Insights Into Hypertension Dickinson W. Richards Memorial The Road Ahead Management Lecture Hypertension and Nephrology 10:30-11 a.m. 1:30-2:45 p.m. Disruptive Solutions (Part 1): 3:45-5 p.m. Main Event: Coagulopathies Artificial Intelligence Sweet Spot in Cardiometabolic Care in Resuscitation Lifestyle & Behavioral Medicine 11-11:30 a.m. 3:15-4:30 p.m. Disruptive Solutions (Part 2): Main Event: Pharmacologic Sensors and Diagnostics MAIN EVENT SESSIONS Resuscitation Therapies

11:45 a.m.-12:30 p.m. 9-10:15 a.m. 4:30-5:30 p.m. Technology Pull vs. Push: Technology and Health Care: Oral Abstracts A Focus on Unmet Needs The Road Ahead Health Tech 2:45-3:30 p.m. SIMULATION ZONE Best Abstracts in Health Tech 10:45 a.m.-Noon Taking on the Tidal Wave: 9-10:15 a.m. 3:30-3:55 p.m. Forefront of Diabetes Care Hemodynamic Simulation: Health Tech Competition: Cardiometabolic Health and Diabetes Hemodynamics Live: Shock: Etiology Where Are They Now? and Intervention Simulation 12:30-1:30 p.m. Community: Heart Failure and Cardiomyopathies 3:55-4:25 p.m. Lasker Laureate Lecture Scaling Innovations in Academic Cross Specialty 10:15-10:45 a.m. Health Systems? Body Interact: Coronary Intervention 2-3:15 p.m. Community: Acute Coronary Syndromes 4:45-5:30 p.m. 2017 Hypertension Clinical Practice Regulatory and Reimbursement Guidelines 10:45-11:15 a.m. Strategy Hypertension and Nephrology Cardiovascular Interventional: Valvular Heart Disease Simulation: 5:30-6 p.m. 2-3:15 p.m. TAVR III Digital Health Industry: Hype or Real? Treating ACS in 2017 and Beyond Community: Interventional Treatments Acute Coronary Syndromes 10:45 a.m.-Noon INTERVENTIONAL CENTRAL 3:45-5 p.m. Hemodynamic Simulation: Avoiding Failure in Heart Failure Care Hemodynamics Live: 10-11 a.m. Heart Failure and Cardiomyopathies Pediatric VAD Simulation Challenging Interventional Cases Community: Congenital Heart Disease and Community: Interventional Treatments Pediatric Cardiology

1-2:15 p.m. 11:15-11:45 a.m. Building a Successful IC Career Path: Cardiovascular Interventional: The First Five Years Coronary Intervention Simulation: Community: Interventional Treatments Catheterization Skills Community: Interventional Treatments

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 16 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. 11:45 a.m.-12:15 p.m. TUESDAY, FOGARTY, NHLBI, NIH AND Body Interact: Valvular Heart THE FUTURE OF GLOBAL Disease NOV. 14 CARDIOVASCULAR HEALTH Community: Interventional Treatments RESEARCH Community: Cross Specialty 11:45 a.m.-12:30 p.m. CARDIOVASCULAR SimMan Vascular: Acute Ischemic NURSING CLINICAL 2-3:15 p.m. Stroke II SYMPOSIUM Introduction Community: Interventional Treatments 8 a.m. 3:45-5 p.m. 2-3:15 p.m. Opening Remarks Priority Research and Research Hemodynamic Simulation: Methods for Global Cardiovascular Hemodynamics Live: What Now? 8:10 a.m. Health VAD Tricks and Troubles Session 4: Keynote – ECC Monitoring: Community: Heart Failure and Cardiomyopathies Revelations from the PULSE 5:30-6:45 p.m. (Practical Use of the Latest Standards Early Career Global Cardiovascular 3-3:30 p.m. of Electrocardiography) Trial Research Cardiovascular Interventional: Endovascular Intervention Simulation: 9 a.m. Peripheral Angiography Session 5: Integrating the VAD, FRONTIERS IN SCIENCE: Community: Interventional Treatments Transplant and LifeVest Patient Back STEM CELLS SUMMIT Into Their Community Community: Cellular Biology 3:30-4 p.m. Cardiovascular Interventional: 10 a.m. 9-10:15 a.m. Cardiac Electrophysiology Simulation: Session 6: Cardiotoxicity of New Concepts in Progenitor Cell Basic Skills Recreational Drugs: Exploring the Biology Community: Electrophysiology and Arrhythmias "Ecstasy” With the Pharmacology 10:45 a.m.-Noon 3:30-4:15 p.m. 10:45 a.m. Tissue Engineering and iPSCs SimMan Vascular: Acute Myocardial Session 7: Panel Discussion – Infarction II Updates in Structural Heart Disease 2-3:10 p.m. Community: Interventional Treatments Paracrine Mechanisms and 12:45 p.m. Methodological Aspects 3:45-5 p.m. Session 8: Tackling Mysterious Hemodynamic Simulation: Dysrhythmias: Differentiation Wide 3:25-5 p.m. Hemodynamics Live: QRS Complex Tachycardias Clinical Studies of Cell Therapy I Transpulmonary to Soaring CVP Community: Heart Failure and Cardiomyopathies 1:30 p.m. 5:15-7 p.m. Session 9: Coagulation Modifiers: Clinical Studies of Cell Therapy II 5:30-6:45 p.m. Managing the Stroke Patient Who Hemodynamic Simulation: Is Bleeding Hemodynamics Live: VADs ASAP: FRONTIERS IN SCIENCE: From Save to Bridge 2:15 p.m. VASCULAR DISEASE Community: Heart Failure and Cardiomyopathies Session 10: Underutilization of SUMMIT Cardiac Rehab: Overcoming Barriers and Improving Outcomes 3:45-5 p.m. Evolving Concepts in Peripheral Vascular Intervention EP CENTRAL 5:30-7 p.m. 12:15-1:15 p.m. New Looks at Atherogenesis and Charting the Course Toward a Therapeutic Approaches in PAD Successful EP Career Community: Electrophysiology and Arrhythmias

Data current as of Sept. 5. scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 17 Continued from page 17 2-3:15 p.m. 12:15-12:45 p.m. Eradicating Atherosclerotic CVD: Cardiovascular Interventional: New Drugs for Reducing ApoB- Valvular Heart Disease Simulation: INTERVENTIONAL CENTRAL Containing Lipoproteins TAVR IV Arteriosclerosis, Thrombosis, Vascular Biology Community: Interventional Treatments 11 a.m.-12:15 p.m. Top Five Innovations That Will 2-3:15 p.m. 12:45-1:15 p.m. Change the Interventional Cardiology Cardio-Oncology: Two Killers Collide Body Interact: Arrhythmias Field Vascular Disease and Thrombosis Community: Electrophysiology and Arrhythmias Community: Interventional Treatments 3:45-5 p.m. 1:15-1:45 p.m. 1-2 p.m. One Size Doesn’t Fit All – Difficult Cardiovascular Interventional: Funding for Your Great Ideas Decisions in Prevention Practice Coronary Intervention Simulation: Community: Interventional Treatments Prevention, Health and Wellness Advanced Skills Community: Interventional Treatments

LATE-BREAKING SCIENCE PRECISION MEDICINE 1:30-2:15 p.m. SimMan Vascular: Acute Myocardial 10:45 a.m.-Noon 9-10:15 a.m. Infarction IV New Insights Into the Risks, The Future of Precision Medicine Community: Interventional Treatments Benefits and Costs of Antithrombotic and Big Data Therapy Arteriosclerosis, Thrombosis, Vascular Biology 10:45 a.m.-Noon WEDNESDAY, Rapid-Fire Reports From the Front 3:45-5 p.m. Lines NOV. 15 Evaluating Quality Improvement and Patient-Centered Care 2-3:15 p.m. Interventions Improving Precision in Cardiomyopathies LATE-BREAKING SCIENCE Quality of Care 3:45-5 p.m. 9-10:15 a.m. Precision in Action Innovative Therapies and Novel MAIN EVENT SESSIONS Applications Heart Failure and Cardiomyopathies 9-10:15 a.m. SIMULATION ZONE Precision Medicine Summit: The Future of Precision Medicine 10:15-10:45 a.m. MAIN EVENT SESSIONS and Big Data Cardiovascular Interventional: Genetics and Genomics Coronary Intervention Simulation: 9-10:15 a.m. Complex Cases Trending Topics in Population Science 9-10:15 a.m. Community: Interventional Treatments Cross Specialty Break Down Those Walls … Frontiers in Team-Based Structural Interventions 10:45-11:15 a.m. 10:45 a.m.-Noon Interventional Treatments Body Interact: Acute Ischemic Stroke Trending Topics in Clinical Science and Syncope Cross Specialty 10:45 a.m.-Noon Community: Stroke & Neuroscience Emerging Evidence Base for the 10:45 a.m.-Noon Treatment of Peripheral Artery 11:15-11:45 a.m. Trending Topics in Basic Science Disease Cardiovascular Interventional: Cross Specialty Vascular Disease and Thrombosis Endovascular Intervention Simulation: Iliac/SFA Intervention 12:30-1:30 p.m. Community: Interventional Treatments Distinguished Scientist Lecture 11:15 a.m.-Noon SimMan Vascular: Simulation 5 Community: Interventional Treatments

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 18 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. AA November 10-14 April 2018

MARK YOUR AA #AHA1

IVIE-86719_Ascend_Oct_R2.indd 3 9/15/17 2:36 PM MEET THE AHA SCIENTIFIC SESSIONS 2017 FACULTY

A Thomas Allison Anita Asgar Cristina Basso Gerald Bloomfield Priscila Bueno Suhny Abbara Alvaro Alonso Euan Ashley Anupam Basuray Laura Blue Raffaele Bugiardini Antonio Abbate Jamilah AlRahimi Samuel Asirvatham Eric Bates David Bluemke Thomas Bunch J. Dawn Abbott Laith Alshawabkeh Stella Aslibekyan Katherine Bates Elizabeth Blume Gregory Burke Jinnette Abbott Carolyn Altman Folkert Asselbergs John Batsis Bentley Bobrow Lora Burke Willie Abel Jesus Alvarez Garcia Dianne Atkins Jeroen Bax Simon Body Daniel Burkhoff Jake Abernathy Sebastian Ameriso Pavan Atluri Bryn Baxendale Harm Bogaard John Burnett Charbel Abi Khalil Ahmad Amin Tom Aufderheide Rob Beanlands Frank Bogun Jane Burns Ruhul Abid Amit Amin Eric Austin Andrea Beaton Roberto Bolli Kristin Burns Victor Aboyans Celso Amodeo Jennifer Avari Silva Lance Becker Marc Bonaca Paul Burridge Federica Accornero Ezra Amsterdam Hakan Ay Richard Becker Daniel Bonneau Elan Burton Tushar Acharya Inder Anand Felix Ayala-Paredes Joshua Beckman Damien Bonnet Noël Burtt Stephan Achenbach Sonia Anand Steffie Beesems Sebastien Bonnet John Buse Michael A. Acker Veera Anantha B Atta Behfar Robert Bonow Jonathan Butcher Michael Ackerman Kasper Andersen Anvar Babaev Elijah Behr William Borden Javed Butler Maegen Ackermann Jeffrey Anderson Emile Bacha Roy Beigel Jan Boren Denis Buxton Selcuk Adabag Mark Anderson Johannes Backs Amber Beitelshees Barry Borlaug Barry Byrne Daniel Addison Monique Anderson Feras Bader Branko Beleslin Daniela Börnigen Prachi Agarwal Starks Mary Kay Bader Jason Gary Bellet Luiz Bortolotto C Stefan Agewall Felicita Andreotti Lina Badimon John Beltrame Jackie Bosch Antonio Cabrera Giancarlo Agnelli Brian Annex M. Badiuzzaman Emelia Benjamin Kristina Bostrom Robert Califf David Aguilar Sameer Ansari Mitesh Badiwala Ivor Benjamin Nabila Bouatia-Naji Hugh Calkins Frank Aguirre Elliott Antman Akshay Bagai Raymond Benza Jamieson Bourque John Calvert Farooq Ahmed Charalambos Aaron Baggish Jeffrey Berger Kate Bowen Duke Cameron Masood Ahmed Antoniades Christopher Baines Daniel Berman Louise Bowman Paolo Camici Nazir Ahmed Charles Antzelevitch Annette Baker Peter Bernhardt Jack Boyd John Camm Chowdhury Ahsan Piero Anversa Carissa Baker-Smith Daniel Bernstein Noel Boyle Umberto Campia Elena Aikawa Saif Anwaruddin Abigail Baldridge Kathy Berra Biykem Bozkurt Christopher Cannon Sophia Airhart Kazutaka Aonuma H. Scott Baldwin Angela Bersch-Ferreira David Bradley Mary Canobbio Jassim Al Suwaidi Lawrence Appel Christie Ballantyne Otavio Berwanger Elisa Bradley Warren Cantor Amin Al-Ahmad Francisco Arabia Margaret Ballantyne Angelyn Bethel Steven Bradley John Canty Sana Al-Khatib Alev Arat Ozkan Brandon Ballinger Aruni Bhatnagar Kelley Branch Pellegrini Cara Mouaz Al-Mallah Eloisa Arbustini Peter Baltrus Deepak Bhatt David Brasil Robert Carey Mika Ala-Korpela Stephen Archer Subhash Banerjee Prashant Bhave Lisa Bratzke Mercedes Carnethon Hasan Alam Hossein Ardehali Sripal Bangalore Ravinay Bhindi Lynne Braun Lucie Carrier Samir Alam Reza Ardehali Puja Banka Kirsten Bibbins- Eugene Braunwald Brett Carroll Christine Albert Gowthami Arepally Aneesh Bapat Domingo Khadijah Breathett April Carson Michelle Albert Venkatesh Arjun Yaniv Bar-Cohen Bruce Biccard Christopher Breuer Brett Carter Nancy Albert Ines Armando Ana Barac Martha Biddle Luke Brewster Paul Casale Pilar Alcaide Aimee Armstrong Adrian Baranchuk Robert Biederman Emmanouil Brilakis Joao Cavalcante Micheala Aldred Donna Arnett David Barefield Mark Bieniarz Evan Brittain Yong-Mei Cha John Alexander Suzanne Arnold Susan Barnason George Billman Daniel Brodie Alejandro Chade Erick Alexanderson- Herbert Aronow Geoffrey Barnes Ulrika Birgersdotter- Joan Heller Brown Anwar Chahal Rosas Pankaj Arora Suzanne Baron Green Todd Brown Tarun Chakravarty Hussam AlFaleh Rakesh Arora Gregory Barsness David Birnie James Bruce Matthew Cham Joakim Alfredsson Kent Arrell Philip Barter Cynthia Bither Ramon Brugada Julian Chan Mumtaj Ali Elva Arrendo John Bartholomew Marcio Bittencourt Bianca Brundel Kwan Chan Larry Allen Nancy Artinian Rebecca Bartlett Ellis Vera Bittner Benoit Bruneau Matthew Chan Norrina Allen Federico Asch Jason Bartos Stefan Blankenberg Chiara Bucciarelli-Ducci Stephen Chan Matthew Allison Deborah Ascheim Monica Baskin Burns Blaxall Harleah Buck Timothy Chan

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 20 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. Jaya Chandrasekhar Monica Colvin Charles Deakin Stavros Drakos Anthony Chang Anthony Comerota Barbara Deal Mark Drazner Abhishek Chaturvedi Bruce Conklin Steven Dean Rachel Dreyer Yiannis Chatzizisis Stuart Connolly Abe Deanda Konstantinos Drosatos of the BEST Irshad Chaudry C. Richard Conti Arjun Deb Xiaoping Du Dennis Cheek Deborah Cook Prakash Deedwania Anne Dubin presentations to attend while at AHA Haodong Chen Jennifer Cook Thomas Deering Dariusz Dudek Scientific Sessions 2017. Hong Chen Nancy Cook Andrew DeFilippis P. Barton Duell 5 Ju Chen Lauren Cooper Mario Delmar Jonathan Dukes Lin Chen Mary Cooter Anthony DeMaria Dirk Duncker 2017 Hypertension Clinical Minglong Chen John Coppola Linda Demer Shannon Dunlay Practice Guidelines Shaochen Chen Jan Cornel Spiros Denaxas Daniel Duprez Nov. 13 Shiyou Chen Marco Costa Ali Denktas Ernesto Duronto • Robert Carey • William Cushman Xin CHEN Shaun Coughlin Joshua Denny Bram Duyx • Kenneth Jamerson Yabing Chen Benoit Coutu Rajat Deo Victor Dzau • Paul Muntner Zhaoyun CHENG Chad Cowan Akshay Desai • Sandra Taler Albert Cheung Deborah Crabbe Ankit Desai E • Rhian Touyz Pratik Chhatbar Filippo Crea Mehul Desai Zubin Eapen • Paul Whelton Neil Chi Mark Creager Nehar Desai Jo-Ann Eastwood Shu Chien Esther Creemers Nihar Desai Ray Ebert Clinical Practice Guidelines William Chilian Michael Criqui Isabelle Deschenes Robert Eckel for Blood Pressure Management: Marshall Chin Rosanne Crooke Hector Deschle Lee Eckhardt Next Steps Kavitha Chinnaiyan Sara Cuccurullo Jean-Pierre Després Kathy Economy Nov. 13 • Wilbert Aronow Richard Chinnock Marina Cuchel Anita Deswal Thor Edvardsen • Robert Carey Christine Chiu-Man Phillip Cuculich Raji Devarajan Rachael Edwards • Donald Casey Donghoon Choi Bettina Cuneo PJ Devereaux Igor Efimov • Daniel Jones Jaehyuk Choi Luke Cunningham Richard Devereux John Eikelboom • Sidney Smith Jasmine Choi Anne Curtis Chandan Devireddy Mikhael El-Chami • Paul Whelton James Chong Jeptha Curtis Holli DeVon Ismail El-Hamamsy • Jackson Wright Niteesh Choudhry Mary Cushman Cameron Dezfulian Uri Elkayam Sheryl Chow William Cushman Kumar Dharmarajan Patrick Ellinor Health Tech Summit: Technology Shahryar Chowdhury Jeffrey Cutler Navneet Dhillon Perry Elliott & Health Care: The Road Ahead Somanathan Lawrence Czer Ravi Dhingra Christopher Ellis Nov. 13 • James Mault Chozhakkat Luigi Di Biase Stephen Ellis • Jessica Mega Rob Christenson Andrea Di Lenarda David Ellison D • Dennis Schmuland Meyhoff Christian Andre D’Avila Gabriele Di Luozzo Sandra Elman • Sue Siegel Christina Christoffersen Nagib Dahdah José Diaz Jonathan Elmer Sumeet Chugh Hiroyuki Daida Victoria Dickson John Elrod Fogarty, NHLBI, NIH and the Hyung Chun Michael Dake Deborah Diercks Mark Engel Future of Global Cardiovascular Eugene Chung Lucas Damiani J. Michael DiMaio Gregory Ensing Health Research Mina Chung Scott Damrauer Stefanie Dimmeler David Erlinge Nov. 14 Sheng-chia Chung Goodarz Danaei J. Dionne-Odom Sabine Ernst • Gerald Bloomfield • Goodarz Danaei Keith Churchwell Stephen Daniels Anne Dipchand Ngozi Erondu • Valentin Fuster Janice Chyou Alejandro Dapelo Thomas Disalvo Thomas Eschenhagen • Tom Gaziano Eugenio Cingolani Alan Daugherty Ana Djordjevic-Dikic Vidal Essebag • Roger Glass Allison Cirino Stephen Davidow Dobromir Dobrev Jerry Estep • Mark Huffman John Clark Michael Davidson Milan Dobric Mark Estes • George Mensah Shanelle Clarke Piroze Davierwala John Dodson Christian Etz • Dorairaj Prabhakaran J. Perren Cobb Martha Daviglus Scott Doheny Lorraine Evangelista • Srinath Reddy Rebecca Cogswell Jennifer Davis Mary Dolansky Gregory Evans • Amy Sims Ariel Cohen Michael Davis Kathryn Domanchuk Natalie Evans • Karen Sliwa David Cohen Buddhadeb Dawn Ibrahim Domian Brendan Everett • Tecla Temu Mauricio Cohen Sharlene Day Michael Donnino Melanie Everitt Precision Medicine Summit: Meryl Cohen Julie De Backer Mary Donofrio Michael Ezekowitz The Future of Precision Medicine Ricardo Cohen Sarah De Ferranti Yoav Dori and Big Data Jay Cohn Gaetano de Ferrari Gerald Dorn F Nov. 14 Lola Coke Vinicio De Jesus Perez Derek Dosdall Peter Fail • Joshua Denny Bernice Coleman James De Lemos Cynthia Dougherty Diane Fairclough • Michael Murray Karen Coleman Giovanni De Simone Tacy Downing Guido Falcone • Michael Pencina Rory Collins Dick de Zeeuw Luciano Drager Rodney Falk

Data current as of Sept. 5. scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 21 Bonita Falkner Gwen Fosse Cecilia Giachelli Jan-Thorsten Gräsner Jeff Healey Priscilla Hsue Harrison Farber D. Brian Foster Raymond Gibbons Eric Green Harvey Hecht Kurt Huber Michael Farkouh Keith A. A. Fox C. Michael Gibson Philip Greenland Don Heck Mark Huffman Edie Farrell Julia Frahya Samuel Gidding Daniel Greif Paul Heidenreich Scott Hummel Joe Farrell Gary Francis Ian Gilchrist Kathy Griendling Lutz Hein Judy Hung David Faxon Gordon Francis Susan Gilchrist Justin Grodin Donald Heistad Sharon Hunt Zahi Fayad Nikolaos Frangogiannis Linda Gillam Lars Grosse-Wortmann Wesam Hejily Judith Hupcey Sergio Fazio Sarah Franklin Gimelli Giorgio Peter Gruber Claes Held Tawfiq Huq William Fearon Charles Fraser Jay Giri Marco Guazzi Tarek Helmy Karen Huss Francesco Fedele Joseph Frassica Robert Giugliano Mayra Guerrero Harry Hemingway Muhammad Hussain Brian Fedor Kelly Frazer Michael Givertz Unjali Gujral Linda Hemphill Paul Hwang Vadim Fedorov Ben Freedman Mark Gladwin Martha Gulati Robert C. Hendel Elaine Hylek Kathleen Fedyszen Donald Frei Brian Glancy Rajiv Gulati Heather Henderson Brian Feingold Stephen Fremes Andrew Glatz Kristine Guleserian Jeroen Hendriks I Frederick Feit Mark Friedberg Thomas Gleason Michele Gulizia Peter Henke Licia Iacoviello Ted Feldman Ruth Frikke-Schmidt Christopher Glembotski Michelle Gumz Nicholai Henry Fukiko Ichida G. Michael Felker Peter Frommelt Taya Glotzer Erica Gunderson Timothy Henry Fumito Ichinose Keith Ferdinand Jennifer Frontera Alexey Glukhov Jack Guralnik Ramon Hermida Satoshi Iimuro Jane Ferguson Tomoyuki Fujita Robert Glynn Paul Gurbel Adrian Hernandez Dimas Ikeoka Dean Fergusson Tohru Fukai Alan Go M. Edip Gurol David Herrington John Ikonomidis Susan Fernandes Yoshimi Fukuoka David Goff Asa Gustafsson Ray Hershberger Tanya Illiadis Rosemarie Fernandez Greg Fulcher Michael Gold Stephanie Gustavson Eyal Herzog Jodie Ingles Francisco Fernandez- Stephanie Fuller Anne Goldberg Gordon Guyatt Joshua Heuslein Ignacio Inglessis Aviles Diaz David Fulton David Goldberg Tomasz Guzik William Hiatt Teruo Inoue Rodrigo Fernandez- Marjorie Funk Ira J. Goldberg Mariann Gyongyosi Kathleen Hickey Silvio Inzucchi Jimenez Karen Furie Zach Goldberger William Hiesinger Nayyar Iqbal Giovanni Ferrari Jose Fuster Sherita Golden H Yusuke Higashi Kaiko Irani Victor Ferraris Valentin Fuster Samuel Goldhaber Richard Ha Ziyad Hijazi Thomas Isaac Jeffrey Ferraro Bryan Goldstein Francois Haddad Bradford Hill Nabeel Ismail Jorge Ferreira G Joshua Goldstein Majid Haghjoo Joseph Hill Eric Isselbacher Vanessa Ferreira Domenico Gabrielli Nathan Goldstein Roger Hajjar Kevin Hill D. Dunbar Ivy Ignacio Ferreira- Joshua Gagne Mardi Gomberg- Saptarsi Haldar Barbara Hinch Hiroshi Iwata Gonzalez Michael Gaies Maitland Michael Halkos Aroon Hingorani Luigi Ferrucci Dan Gaita Delphine Gomez Shannon Halloway Kenzo Hirao J Stephanie Fichtner Nazzareno Galie Elena Goncharova Henry Halperin Takafumi Hiro Tiny Jaarsma John Field Vijay Ganta Karina Gonzalez Jonathan Halperin Karen Hirsch Cynthia Jackevicius Katrina Fields Peter Ganz Jorge Gonzalez Hélio Halpern Mark Hlatky Elizabeth Jackson Gemma Figtree Peggy Gao Gutierrez Naomi Hamburg Ota Hlinomaz Alice Jacobs Laura Findeiss Ying Gao Holly Gooding Mohamed Hamdan Carolyn Ho Jeffrey Jacobs Vicente Finizola Cristina García-Cáceres Sarah Goodlin Tariq Hamid Vincent Ho Jill Jacobs Michael Fischbein Julius Gardin Adam Goodwill John Haney Mélèze Hocini Alan Jaffe Michael Fischer Timothy Gardner Chandrasekar Frank Hanley Marius Hoeper Babak Jahromi David Fischman Sonia Garg Gopalakrishnan Tomoo Harada Timothy Hoffman Rajan Jain Anne Fish Vidu Garg Rajesh Gopinath Ashraf Harahsheh Udo Hoffmann John Jakicic Michael Fishbein Daniel Garry Rakesh Gopinathannair Joshua Hare Kurt Hoffmayer Stefan James David Fitchett Maurizio Gasparini Penny Gordon-Larsen Kishore Harjai Stefan Hohnloser Anwer Jamsheer Donna Fitzsimons J. William Gaynor Bulent Gorenek Robert Harrington John Holcomb James Januzzi Rachel Flach Raúl Gazmuri Heather Gornik Samantha Harris Seth Hollander Robert Jaquiss John Flack Arnar Geirsson Robert Gourdie Stephanie Harris Whitney Hollands John Jefferies Edith Fleischmann Bruce Gelb Ramesh Gowda Willam Harris Rury Holman David Jenkins Talya Fleming Isaac George Masahiko Goya David Harrison Narimon Honarpour Catriona Jennings Barbara Fletcher Jyothis George Mayank Goyal Ahmed Hasan Mun Hong Jacob Jentzer Roberta Florido Lior Gepstein Andrew Grace Thomas Hatsukami Rachel Hopper Tomas Jernberg Mark Fogel Eva Gerdts Kathy Grady Kristina Haugaa Minoru Horie Mariell Jessup Gregg Fonarow Marie Gerhard-Herman Michelle Graham Beth Hawkins Lifang Hou Zhang Jian Roger Foo Robin Germany Eleonora Grandi Sharonne Hayes Steven Houser Zheng Gen Jin Rhondalyn Bernard Gersh Michael Grandner Mark Haykowsky Tzung Hsiai Hani Jneid Forde-McLean Edward Gerstenfeld Bradi Granger Laura Hayman Patrick Hsieh Hanjoong Jo Paul Forfia Robert Gerszten Christopher Granger Stanley Hazen Chung Hsu Jose Joglar Daniel Forman Mauro Giacca Elena Grant David He Daphne Hsu Anitha John

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 22 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. Karen Johnson Prateeti Khazanie Richard Krasuski Leslie Leinwand Steven Lubitz Scot Matkovich Rachel Johnson Amit Khera Catherine Krawczeski Erin Leister Yee-Bun Benjamin Lui Daniel Matlock Sanjit Jolly Kiran Khush Jacqueline Kreutzer Lawrence Leiter Thomas Lüscher Simon Matskeplishvili Daniel Jones Melina Kibbe Eric Krieger Carolyn Lekavich Aldons Lusis Reiko Matsui Emily Jones Gregory Kicska Penny Kris-Etherton Scott Lemaire Susanne Lutz Alan Matsumoto Greg Jones Michael Kiernan Prasanna Krishnamurthy Terry Lennie Yuji Matsuzawa Steven Jones Yasuki Kihara Mangalath Krishnan Steven Lentz M David Matthews William Jones Ahmet Kilic Jordana Kron Jane Leopold Christoph Maack David Mattson Torben Jorgensen Arman Kilic Harlan Krumholz Bradley Leshnower Roberto Machado Susan Matulevicius Huizar Jose Byeong-Keuk Kim David Krummen Kate Leslie Calum MacRae James Mault Johny Joseph Dennis Kim Karl Hein Kuck John Lesser Michael Madani Mathew Maurer Susan Joseph Esther Kim Peter Kudenchuk Benjamin Levine Thomas Maddox Laura Mauri Karen Joynt Jonathan Kim Julia Kuder Glenn Levine Nicolas Madsen Pal Maurovich-Horvat Daniel Judge Takeshi Kimura Iftikhar Kullo Jerrold Levy Katsuhide Maeda Manuel Mayr J. Wouter Jukema Steven Kindel Monisha Kumar Michael Levy Aldo Maggioni C. Mazer Corrine Jurgens Bronwyn Kingwell R. Krishna Kumar Wayne Levy Gayenell Magwood Ramesh Mazhari Scott Kinlay Raman Kumar Thorsten Lewalter Vaikom Mahadevan Michael McConnell K Abdulhalim Kinsara Dharam Kumbhani Basil Lewis Kenneth Mahaffey Brian McCrindle Allen Kachalia Annet Kirabo Christopher Kurtz Cora Lewis Aman Mahajan Peter McCullough Susan Kahn James Kirkpatrick Michael Kurz Eldrin Lewis William Mahle James McCully Rami Kahwash Jacobo Kirsch Kari Kuulasmaa Gregory Lewis Ahmed Mahmoud Michael McCurdy Koichi Kaikita Roxanne Kirsch Jennifer Kwong Sandra Lewis Alan Maisel Mary McDermott Petr Kala Lorrie Kirshenbaum Raymond Kwong Chuanfu Li Mark Majesky Alicia McDonough Kamyar Kalantar-Zadeh Raj Kishore Bonnie Ky Na Li Nour Makarem Doff McElhinney Eliyahu Kalfon Aaron Kithcart Tao Li Jonathan Makielski Anthony McGuire Antony Kaliyadan Lisa Kitko L David Liang Raj Makkar Colleen McIlvennan Andreas Kalogeropoulos Richard Kitsis André La Gerche Ronglih Liao S. Christopher Malaisrie William McKenna Jonathan Kaltman Michelle Kittleson Daniel Lackland Peter Libby Konstantinos Maliaris Timothy McKinsey Estella Kanevsky Dalane Kitzman Mary Jo LaDu John Lichtenberger Fazila Malik Vallerie McLaughlin Yogendra Kanthi Deborah Klein Najim Lahrouchi Alice Lichtenstein Hari Mallidi David McManus Suraj Kapa Jeffrey Kline Neal Lakdawala Gisella Lilja Mekhman Mamedov Julie McMullen Daniel Kapusta Leonie Klompstra Dhanunjaya Lakkireddy Scott Lilly Pradeep Mammen John McMurray Mahir Karakas Robert Kloner Ashwin Lal Joao Lima Donna Mancini Michael McMurtry Tara Karamlou Reinoud Knops Anuradha Lala Bertil Lindahl John Mancini Elizabeth McNally Keyvan Karkouti Alana Knudson Maggie Lam Lars Lindhagen John Mandrola Dennis McNamara Ronald Karlsberg Kristen Knutson Linda Lambert Jonathan Lindner Rekha Mankad Jean McSweeney Jason Karnes Juhani Knuuti Rachel Lampert Mark Lindsay Douglas Mann Clive Meanwell Ganesan Karthikeyan Taisei Kobayashi Andre Lamy Merry Lindsey Eduardo Marban Jeff Meeusen Denuja Karunakaran Walter Koch Martin Landray Mark Link Linda Marban Jessica Mega Sekar Kathiresan Lazaros Kochilas Andrew Landstrom Dominik Linz Michael Marber Mandeep R. Mehra Jason Katz Robb Kociol David Lanfear Gregory Lip Gregory Marcus Roxana Mehran Beth Kaufman Susheel Kodali Shane LaRue Freddy Lippert Christine Maric-Bilkan Laxmi Mehta Sanjay Kaul Kwang Koh Joe Lau Sheldon Litwin Jose Marin-Garcia Shamir Mehta Sunjay Kaushal Mark Kohr Julie Lauffenburger Peter Liu Bradley Marino Ju MEI Clifford Kavinsky Ralf Kolvenbach Carl Lavie Donald Lloyd-Jones Bradley Maron Peter Meikle Steven Kawut Stephen Kolwicz Patrick Lawler Cecilia Lo Alison Marsden Olivier Meilhac David Kaye Issei Komuro Jennifer Lawton James Lo Steve Marso Matthew Mell Martin Keane Dimple Kondal Jean-Yves Le Heuzey Armando Lobato Steven Marso Matthew Menard Mark Kearney Wei Kong Miguel Leal Yuliya Lokhnygina Cindy Martin Philippe Menasche Elvin Kedhi William Kok-Fai Kong Marion Leary William Lombardi James Martin Ivan Mendoza Mary Keebler Marvin Konstam Linda Leatherbury Chris Longenecker Seth Martin Venugopal Menon Anthony Keech Maria Kontaridis Christophe Leclercq Eva Lonn Alejandro Martinez George Mensah Sebastian Kelle Gideon Koren Anson Lee Gary Lopaschuk Felipe Martínez Robert Mentz Thomas Kellerth Maria Korre Christopher Lee Jaime Lopez Tami Martino Mark Mercola Daniel Kelly Anna Kostareva Laurel Lee Jose Lopez Peter Mason Ahmed Merghani Noreen Kelly Rudolph Koster Marianne Lee Lenny Lopez R. Mason Luc Mertens Dean Kereiakes Jacqueline Kraft Barbara Leeper Angela Lorts Frederick Masoudi Noel Merz Morton Kern Daniel Kramer Nicholas Leeper Joseph Loscalzo Joseph Massaro Katie Meyer Aarif Khakoo Jo Kramer-Johansen David Lefer Douglas Losordo Joseph Mathew Nuala Meyer Sadiya Khan Evangelia Kranias Leanne Lefler Mary Lough Wilson Mathias Evangelos Michelakis

Data current as of Sept. 5. scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 23 Robert Michler N Michelle O’Donoghue Himanshu Patel Daniel Piskorz Jacob Raphael Erin Michos Vinay Nadkarni Patrick O’Gara Lajja Patel Bertram Pitt Mathias Rask-Andersen Ricardo Migliore Ryozo Nagai Daniel Ocazionez Manesh Patel Jeffrey Platt Annica Ravn-Fischer Evgeny Mikhaylov Matthias Nahrendorf Hisao Ogawa Prakash Patel Mark Pletcher Kausik Ray David Milan Srihari Naidu Gbenga Ogedegbe Pranav Patel Jennifer Pluznick Katey Rayner Carmelo Milano Yoshihisa Nakagawa Takeshi Ogo Rajeev Pathak Oleh Pochynyuk Thomas Rea Dianna Milewicz Atsushi Nakano Hidemasa Oh Pravin Patil Mihai Podgoreanu Vicie Reales John Miller Brahmajee Nallamothu Young Oh Bray Patrick-Lake Eugene Podrez Fabio Recchia Michael Miller Navin Nanda Yasuo Ohashi Kristen Patton Steven Poelzing Gautham Reddy Todd Miller Vivek Nanda E. Magnus Ohman Roxane Paulin Janice Pogoda Sushma Reddy Nicholas Mills Sanjiv Narayan Erik Magnus Ohman Walter Paulus Kian-Keong Poh Vivek Reddy Tohru Minamino Sandra Narayanan Peter Öhman W. Frank Peacock Paul Poirier Margaret Redfield Mariana Mirabel Bruno Nascimento Richard Ohye David Pearce Sean Pokorney Marwan Refaat Sanjay Misra Samrah Naseem Francisco M. Ojeda William Pearce Peter Pollak Judith Regensteiner Seema Mital Khurram Nasir Theresa Olasveengen Gail Pearson Tamar Polonsky Jalees Rehman Christina Miyake Andrea Natale Jonas Oldgren Terje Pedersen Arden Pope James Reiffel Shelley Miyamoto Rama Natarajan Glaucia Oliveira Michele Pelter Matthew Popplewell Muredach Reilly Makoto Miyazaki Syam Natesan Juliana Oliveira Constantino Pena Neil Poulter Alan Remaley Bijan Modarai Stanley Nattel Laura Olivieri Michael Pencina Thomas Povsic Gwen Rempel Padinhare Mohanan Patrice Nault Iacopo Olivotto David Peng Tiffany Powell Jun Ren Nathalie Moise Ann Navar Peter Ong Lynn Peng Bunny Pozehl Stacey Rentschler Ezequiel Molina Francisco Naya Suzanne Oparil Martin Penicka Dorairaj Prabhakaran Frederic Resnic Jeffery Molkentin Chiadi Ndumele Karen Ordovas Daniel Penny Sumanth Prabhu Gustavo Restrepo Gilles Montalescot Bruce Neal Ali Oto Amanda Perak Aruna Pradhan Karen Reue Emma Monte Ian Neeland Öztekin Oto Martin Percy Siddharth Prakash Kathryn Rexrode Frederico Monteiro Robert Neumar Catherine Otto Naveen Pereira Ioana Preston Harmony Reynolds Anita Moon-Grady Jane Newburger Bruce Ovbiagele Adriana Perez Jack Price Matthew Reynolds Ernest Moore David Newby Anjali Owens Marco Perez Silvia Priori Ahmad Rezq Kelly Moore L. Kristin Newby Gabe Owens Emerson Perin Steeve Provencher Christopher Rhodes Shirley Moore Jonathan Newman Gary Owens Ben Perkins Steve Provencher Mark Ricciardi Samia Mora Mary Newman Yukio Ozaki Gavin Perkins Jordan Prutkin Michael Rich Julieta D. Christopher Necla Ozer Vlado Perkovic William Pu Paul Ridker Morales-Portano Newton-Cheh Kathleen Ozsvath Harris Perlman Giuseppe Pugliese Barbara Riegel Pedro Moreno Graham Nichol Sarah Perman Mar Pujades-Rodriguez Crystal Ripplinger Patrick Moriarty Stephen Nicholls P Eduardo Perna Soni Savai Pullamsetti Michael Risbano Peter Morley Jacinda Nicklas Rene Packard Frederic Perros Nicole Purcell Rebecca Ritchie Pamela Morris Alina Nicoara Douglas Packer Karlheinz Peter Jon Rittenberger Shaine Morris Jose Nicolau Milton Packer Eric Peterson Q Belinda Rivera-Lebron Laurie Morrison Chris Nielsen Muralidhar Padala Mark Peterson Arman Qamar Pamela Ro David Morrow Marvin Nieman Richard Page Pam Peterson Atif Qasim Jason Roberts Debra Moser Thoralf Niendorf Robert Page Christopher Petit Lu Qi Jennifer Robinson Javid Moslehi Bo Nilsson Neha Pagidipati Mark Petrie Gangjian Qin Joshua Robinson Cleonice Mota MingMing Ning Elfriede Pahl Gosta Pettersson Lauryn Rochlen Zuzana Motovska Akihiko Nogami Igor Palacios Egon Pfarr R Frank Rockhold Marko Mrkobrada Anju Nohria Latha Palaniappan Marc Pfeffer Marlene Rabinovitch Howard Rockman Gia Mudd-Martin Matias Nordaby Ashvin Pande Duc Pham Milica Radisic Stanley Rockson Jochen Muehlschlegel Borge Nordestgaard Peter Pang Francois Philippon Geetha Raghuveer Mark Rodefeld Willem Mulder Kari North Oliver Panzer Clifford Phillips Ansaar Rai Dan Roden Elizabeth Murphy Patricia Noujaim Michael Papadakis Mariann Piano Sudarshan Rajagopal Carlos Rodriguez Michael Murphy Ntobeko Ntusi Andreas Gregory Piazza Prabhakar Rajiah Fatima Rodriguez Sabina Murphy Maria do Carmo Nunes Papapetropoulos Philippe Pibarot Ambady Ramachandran Annabelle Jenna Murray Udi Nussinovitch Nisha Parikh Jonathan Piccini Srinivas Ramaka Rodriguez-Oquendo Katherine Murray Nancy Nussmeier Dukwoo Park Nicholas Pietris Subha Raman Matthew Roe Michael Murray Michaela Nuttall Joel Parlow John Piette Ravichandran Marco Roffi Sarah Murthi Laura Pasea Daniel Pijnappels Ramasamy Veronique Roger Vemuri Murthy O Sara Pasquali Nancy Pike Basel Ramlawi Anand Rohatgi Jihad Mustapha Matt O’Brien Amit Patel Ileana Pina Benjamin Ranard Jonathan Rome Kiran Musunuru Terrence O’Brien Bakul Patel Armando Lira Pineda Sunil Rao Eric Roselli Timothy O’Connell Chetan Patel Peipei Ping Vidya Rao Michael Rosen Christopher O’Donnell Hemal Patel Fausto Pinto Vivek Rao Kenneth Rosenfield

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 24 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. Robert Rosenson S Raul Santos Robert Schwartz Aditya Sharma Akhilesh Sista Robert Ross Marc Sabatine Renato Santos Benjamin Scirica Kavita Sharma Christopher Skelly Marcello Rota Hani Sabbah Eliana Santucci Luca Scorrano Samin Sharma Mark Slaughter Greg Roth Craig Sable Amy Sanyahumbi Iain Scott David Shavelle David Slotwiner Ulrick Rother Michael Sack John Sapp Eric Secemsky Wayne Shaw Eric Small Susan Rowell Frank Sacks Gary Satou David Seder Islam Shawky Sidney Smith Ronen Rubinshtein Sakthivel Sadayappan Naveed Sattar Mike Seed Lina Shehadeh Allan Sniderman Rachel Ruckdeshel Anita Sadeghpour Michael Savage Ellen Seely Nadine Shehata Joni Snyder Smith Hesham Sadek Jacqueline Saw Yoshihiko Seino Farah Sheikh Michael Snyder Jean Marie Ruddy Junichi Sadoshima Yoshiki Sawa Elif Seda Selamet Jonathan Shelton Oliver Soehnlein R. Daniel Rudic Diyar Saeed Richard Schatz Tierney Win Kuang Shen Kyoko Soejima Jeff Rudy Amy Saenger Philip Schauer Frank Sellke Mohammad Shenasa R. John Solaro Marc Ruel Susmita Sahoo Melvin Scheinman Christopher Semsarian Elizabeth Sherwin Daniel Solomon Christian Ruff Hajime Sakuma Ralph Schermuly Partho Sengupta Matthew Sherwood Scott Solomon John Rumsfeld Christopher Salerno Carlos Schiavon Roxy Senior Larissa Shimoda Ransi Somaratne Todd Ruppar Michael Salerno David Schidlow Pablo Sepulveda Hiroaki Shimokawa Virend Somers Mark Russell Heidi Salisbury Ernesto Schiffrin Thomas Sequist Girish Shirali Mary Sorci-Thomas Andrea Russo Tamer Sallam Kelly Schlendorf Michelle Sergel Kalyanam Shivkumar Marcio Sousa John Ryan Fadi Salloum Ann Marie Schmidt Claudia Serrano-Gomez Evgeny Shlyakhto Nicole Spartano Justin Ryan Veikko Salomaa Renate Schnabel Peter Server Kooresh Shoghi Erica Spatz Jack Rychik Flora Sam Paul Schoenhagen Sudha Seshadri Linda Shore-Lesserson Martina Speight Erik Rydberg Habib Samady Jacob Schroder Daniel Sessler Adhir Shroff John Spertus Mikael Ryden Prashanthan Sanders Sam Schulman Robert Shaddy Chrisandra Shufelt Edda Spiekerkoetter Kerry-Anne Rye Roopinder Sandhu Kurt Schumacher Rose Shaffer Lori Shutter Salvador Spina Monika Sanghavi Sarah Amar Shah John Shyy Bonnie Spring Kintur Sanghvi Schumacher-Bass Amil Shah Robert Siegel Deepak Srivastava William Santamore Heribert Schunkert Binita Shah Lee Anne Siegmund Uma Srivatsa Alta Schutte Rashmee Shah Horst Sievert Marie Pierre St Onge Lee Schwamm Sanjiv Shah Alben Sigamani Julie St-Pierre Janice Schwartz Svati Shah Scott Silvestry Cynthia St. Hilaire COMMITTEE Catherine Shanahan Robert Simari Konstantin Stark Scott Shapell Craig Simmons Randall Starling ON SCIENTIFIC SESSIONS Mohsen Sharifi Daniel Sims Alexander Staruschenko PROGRAMMING 2017 Jagmeet Singh Brian Stauffer Mandeep Singh Lyn Steffen Willie M. Abel Anastase Innocent Dinender Singla Sabine Steffens Ben Abella Dzudie Tamdja Pranava Sinha P. Gabriel Steg Stephan Achenbach Zubin Eapen David Siscovick James Stein Norrina Allen David Ellison Eldrin Lewis Robin Steinhorn Larry Allen Michael Fischbein CHAIR Mary Lough Konstantinos Stellos Matt Allison Daniel Forman Eric Peterson, MD, Steve Lubitz MPH, FAHA Sameer Ansari Ian Gilchrist Peter Mason Tom Aufderheide Josh Goldstein Kathryn Rexrode Alan Matsumoto Kenneth Bernstein Martha Gulati Jennifer Robinson Robert Mentz Charles Berul Asa Gustafsson Anand Rohatgi Michael Miller Burns Blaxall Carolyn Ho Kerry-Anne Rye Sanjay Misra Subodh Verma Sebastien Bonnet Tzung Hsiai Craig Sable Kiran Musunuru Tom Vondriska Todd Brown Fumito Ichinose Svati Shah Chiadi Ndumele Yibin Wang VICE CHAIR Tom Cappola Hani Jneid Linda Shore- Ravi Nistala Francine Welty Donald Lloyd- Yabing Chen Jose Joglar Lesserson Jones, MD, ScM, Hisao Ogawa Joshua Willey Keith Chuchwell Steve Jones Alexander FAHA Karen Ordovas Kathy Wood Shanelle Clarke Daniel Jones Staruschenko Latha Palaniappan Sean Wu Deborah Crabbe Pedro Jose Zhongjie Sun Sara Pasquali Robert Yeh Vinicio de Jesus Perez Kiarri Kershaw Jacqueline Manesh Patel Paul Yu David de Padua Brasil Amit Khera Tamis-Holland Kristen Patton Prakash Deedwania Jacob Kirsch Ryan E. Temel Marco Perez Ravi Dhingra Catherine Krawczeski Rong Tian Greg Piazza Jose Diaz Eric Krieger Douglas Tilley AHA PRESIDENT Bunny Pozehl Mark Drazner Dharam Kumbhani Elaine Urbina John J. Warner, MD Aruna Pradhan Andrea Driscoll Miguel Leal Karen Uzark Gautham Reddy Steven Lentz Orly Vardeny Gustavo Restrepo

Data current as of Sept. 5. scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 25 Kurt Stenmark Jennifer Thibodeau Ioanna Tzoulaki Annabelle Volgman Brandon Wiley Yukihiko Yoshida Paul Stephens Holger Thiele Tom Vondriska Jose Wiley Bonnie T. Young Laura Stevens Gaetano Thiene U Wanpen Vongpatanasin John Wilkins Scott Youngquist Lynne Stevenson Patricia Thistlethwaite Shizuka Uchida Adriaan Voors Bruce Wilkoff Paul Yu William Stevenson Venkatakrishna Carlos Uchôa Terri Vrtiska Cristen Willer YiDing Yu Duncan Stewart Tholakanahalli James Underberg Karen Vuckovic James Willerson Fei Yuan Joseph Stigi Dierk Thomas Elaine Urbina Bryan Williams Salim Yusuf Arthur Stillman James Thomas Nir Uriel W David Williams Katherine Yutzey Nathan Stitziel Kevin Thomas Karen Uzark Thomas Wakefield Kim Williams Norman Stockbridge Randal Thomas Reza Wakili David Winlaw Z Neil Stone Sunu Thomas V Ron Waksman Adam Witkowski Justin Zachariah Anna Stromberg Jocelyn Thompson Viola Vaccarino Nathan Waldron Ilan Wittstein Evan Zahn Dion Stub Paul Thompson Amy Vachon Jeanine Walenga Joseph Witztum Neil Zakai Huabo Su Vivian Thompson Vijay Vaidya Lori Walker Steven Wiviott Roham Zamanian Henry Sucov Louise Thomson Hector Valdivia Michelle Wallace Hans Woerle Anna Zampetaki Lisa Suennen Kevin Thorpe Anne Marie Valente Lars Wallentin Wojciech Wojakowski Faiez Zannad Robert Sufit Vinod Thourani Thomas Vallim Kenneth Walsh Alisa Wolberg Andreas Zeiher Il Suh Thomas Thum Volker Vallon Mary Walsh David Wolinsky Tanja Zeller Melanie Sulistio Kristian Thygesen Eric Van Belle Elaine Wan Kai Wollert Jianyi (Jay) Zhang Debbie Summers Lu Tian Jop van Berlo Da-Zhi Wang Nathan Wong Yun Zhang Anne Sumner Rong Tian Pim van der Harst Hong Wang Joseph Woo Lihui Zhao Glen Sumner Rob Tieleman Sean van Diepen Jessica Wang Mary Woo Qiang Zhao Tao Sun Samantha Tierney Jennifer Van Eyk Jian-an Wang Kathryn Wood Bin Zhou Mark Sussman Douglas Tilley Isabelle Van Gelder Jun Wang Malissa Wood Changcheng Zhou David Sutcliffe Adam Timmis Iris van Hagen Paul Wang Pamela Woodard Jiliang Zhou Gopinath Sutendra Tailor Tina George Van Hare Shuang-Xi Wang Jackson Wright Yi Zhu Nancy Sweitzer James Tisdale Eva van Rooij Thomas Wang Janet Wright Yunpeng Zhu Wilson Szeto Thomas Todoran Benjamin Van Tassell Tracy Wang Joseph Wu Peter Zimetbaum Karolina Szummer Lale Tokgozoglu Peter Van Tintelen Xiaowei Wang Richard Wu Lani Zimmerman Catalin Toma Toon van Veen Yibin Wang Sean Wu Wolfram-Hubertus T Gordon Tomaselli Richard Vander Heide Zhao Wang Judith Wylie-Rosett Zimmerman Ira Tabas Wesley Tong Theresa Vander Vennet James Ware Marcin Wysoczynski Bernard Zinman Theresa Tacy Per Tornvall Mani Vannan John J. Warner Matthew Zinn Isao Taguchi Camila Torreglosa Orly Vardeny Jason Wasfy X Andreas Zirlik Michelle Takemoto Rita Tostes Daniel Vargas Jeffrey Washam Denis Xavier Carmine Zoccali Michelle Tallquist Marlin Touma Paul Varosy Christina Wassel Yang Xia William Zoghbi Jacqueline Rhian Touyz Ramachandran Vasan Scott Wasserman Kong Xiangqing Mohammad Zubaid Tamis-Holland Jeffrey Towbin Marmar Vaseghi Karol Watson Jing Wei Xiong Irving Zucker Kenichi Tanaka Dwight Towler George Vatakencherry Janet Wei Qingbo Xu Vikas Tandon Cynthia Tracy Suresh Vedantham William Weintraub Zhiyun Xu Gilbert Tang Jay Traverse Sreekanth Vemulapalli Kenneth Weir Viviany Taqueti Natalia Trayanova Hector Ventura Myron Weisfeldt Y Flavio Tarasoutchi Tom Treasure Marianne Verhaar Robert Weiss Magdi Yacoub Jil Tardiff Diane Treat-Jacobson Atul Verma Jeffrey Weitz Lijing Yan Marja-Riitta Taskinen Jennifer Tremmel Subodh Verma Kristin Weitzel Clyde Yancy Gabriel Tatu-Chitoiu Adriana Tremoulet Suresh Verma Cheryl Wellington Bo Yang Cynthia Taub Quynh Truong Giovanni Veronesi George Wells Phillip Yang Kathryn Taubert Wendy Tsang Kasey Vickers Quinn Wells Demetris Yannopoulos Ahmed Tawakol Allison Tsao Ronald Victor Frederick Welt Yuichiro Yano Doris Taylor Elaine Tseng Mladen Vidovich Francine Welty Satoshi Yasuda Michael Taylor Sotirios Tsimikas Ramya Vijayakumar Nanette Wenger Satoshi Yasukochi Usha Tedrow Georgios Tsivgoulis Chet Villa Jennifer Wessel Oguz Yavuzgil Ryan Temel Patrick Tso Juan Villar James West Robert Yeh Tecla Temu Hugh Tunstall-Pedoe Todd Villines Paul Whelton Khung Keong Yeo Jurriën ten Berg Mintu (Minang) Turakhia Dragos Vinereanu Jennifer White Mehmet Yilmaz Larisa Tereshchenko Sony Tuteja Salim Virani Richard Whitlock Troels Yndigegn Andre Terzic James Tweddell Renu Virmani Petr Widimsky Ajit Yoganathan Jeffrey Testani Marysia Tweet Sami Viskin Debra Wiegand Utako Yokoyama Martin Than Anne Tybjaerg-Hansen Sunita Viswanathan Terri Wiggins Young-Sup Yoon Thenappan Thenappan Wendy Tzou Niels Voigt Jane Wilcox Yoshinori Yoshida

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 26 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. pa i d advertisement

Interactive CME Dinner Symposium Earn 2.5 CME Credits Monday, November 13, 2017

Registration & Dinner 6:30–7:00 pm | CME Symposium 7:00–9:30 pm Hilton Anaheim | California Ballroom D | Anaheim, California

Applying PCSK9 Inhibitors to Optimize Outcomes in Patients With Dyslipidemia

CHAIR Christopher P. Cannon, MD Professor of Medicine Harvard Medical School Executive Director of Cardiometabolic Trials Baim Institute for Clinical Research Senior Physician, Cardiovascular Division Brigham and Women’s Hospital Boston, Massachussetts

AGENDA FACULTY Christie M. Ballantyne, MD pm Professor of Medicine 6:30–7:00 Registration and Dinner Vice-Chair of Research-Department of Medicine Chief-Section of Cardiology Chief-Section of Cardiovascular Research 7:00–7:10 pm Welcome and Introductions Baylor College of Medicine Houston, Texas 7:10–7:25 pm The Evolution of Cholesterol Management Alan S. Brown, MD in Preventive Cardiology Director, Division of Cardiology Advocate Lutheran General Hospital President-Elect, National Lipid Association 7:25–7:30 pm Interactive Expert Panel Discussion Co-Director, Cardiology Service Line Advocate Medical Group Clinical Associate Professor 7:30–7:45 pm New Data from the PCSK9 Trials: Loyola Stritch Medical School FOURIER and Beyond Park Ridge, Illinois Robert H. Eckel, MD 7:45–8:00 pm Lipid Lowering Therapies in Patients Charles A. Boettcher Endowed Chair in Atherosclerosis Division of Endocrinology, Metabolism, and Diabetes With Diabetes Anschutz Medical Center University of Colorado, Denver Aurora, Colorado 8:00–8:10 pm Interactive Expert Panel Discussion

Robert P. Giugliano, MD 8:10–8:30 pm Audience Response: How Should the Associate Professor of Medicine Harvard Medical School Guidelines be Updated? What is Your Take? Senior Investigator, TIMI Study Group Cardiovascular Division Brigham and Women’s Hospital 8:30–8:45 pm Dyslipidemia Guidelines and Practical Boston, Massachussetts Recommendations James A. Underberg, MD, MS Lipidology & Cardiovascular Disease Prevention 8:45–8:50 pm Interactive Expert Panel Discussion Clinical Assistant Professor of Medicine NYU School of Medicine & NYU Center for CV Prevention Director, Bellevue Hospital Lipid Clinic 8:50–9:30 pm Interactive Case Presentation Series President, National Lipid Association New York, New York

This CME activity has been supported by an independent educational grant from Amgen Inc. Provided by

This event is not part of the official Scientific Sessions 2017 as planned by the AHA committee on Scientific Sessions Program.

2017 Preview Preliminary Program 2.indd 1 9/7/17 1:47 PM Thank you to the following exhibitors who have supported this Preview.

EXHIBITORS Get a sneak peek at the exhibitors displaying the latest products and services in the Science & Technology Hall

3D Systems Boehringer Ingelheim Duke Clinical Intermountain Heart A&D Medical Diabetes Research Institute Institute AAT Bioquest, Inc. Boehringer Ingelheim DynaMed Plus/ IonOptix Accusplit Make a Pharma, Inc. EBSCO Health Itamar Medical Difference Programs Boehringer Ingelheim/ eClinicalWorks The JAMA Network ADInstruments, Inc. Eli Lilly Elsevier, Inc. Janssen Advocate Children’s Boston Heart emka Technologies inc Pharmaceuticals Hospital Diagnostics Endothelix, Inc. The Japanese AltaThera Corporation Exemplar Genetics Circulation Society Pharmaceuticals BrainCool AB FDA Center for The Joint Commission Amarin Corporation CAE Healthcare Tobacco Products Kastle Therapeutics Ambry Genetics Cardiology Today and FUJIFILM Laerdal Medical American College Healio.com by VisualSonics Inc. LAMIN-Organic of Cardiology Slack Inc. GeneDx Mouthwash American Heart Cell Applications, Inc. Gilead Sciences, Inc. McGraw-Hill Education Association Inc. CellAegis GuardaHeart The Medicines Amgen Devices Inc. Foundation Company AnaBios Cleveland Clinic Hugo Sachs Elektronik/ Medicure Aralez Pharmaceutical, Contec Medical Harvard Apparatus Medtronic US Inc Systems Co., Ltd. Ideal Protein Memorial Healthcare Arbor Pharmaceuticals Covance, Inc. of America, Inc System AstraZeneca Cytokinetics IEM Mentice Pharmaceuticals DENKA SEIKEN Co., InBody Merck AtriCure, Inc Ltd. Infinity Massage Chairs Millar, Inc. Backpack Health, LLC DMT-USA, Inc. (formerly Infinite Moor Instruments BMS/Pfizer Therapeutics)

While every effort is made to ensure the accuracy of data within this publication, the publisher cannot be 28 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org held responsible for errors or omissions. Highlighted exhibitors shown in bold. Data current as of Sept. 8.

MotherToBaby National Network of Novartis Portola Target BP Wiley Pregnancy Studies Libraries of Medicine Pharmaceuticals Pharmaceuticals, Target HF Wolters Kluwer Multi Channel Systems NEJM Group Corporation Inc. Taylor and Francis WomenHeart: The National Death Index NeuroNexus Novo Nordisk Inc Public Health theheart.org/Medscape National Coalition National Heart, Lung Technologies Outcome Health Foundation of India Cardiology for Women with and Blood Institute Nokia Health Oxford University Press QGenda, LLC TIMI Study Group Heat Disease NHLBI NorthEast Physio-Control Sanofi TSE Systems, Inc. Zero Gravity Skin National Kidney Monitoring, Inc. PhysioWave, Inc. Sanofi Regeneron Type 2 Diabetes Zoll Medical Foundation Northwestern Medicine Pikeville Medical Sanofi/Regeneron Knowledge Portal Corporation National Lipid Nova Innovations Center Medical Information United Biologics Inc. ZS Pharma Association SweetLeaf Stevia VAP Diagnostics Lab Sweetener W.A. Baum Co., Inc.

CARDIOVASCULAR EXPERT THEATERS Spend your lunch time at the Cardiovascular Expert Theaters, products on the market. Complimentary lunch provided by the located in the Science & Technology Hall. Sessions given by American Heart Association. industry supporters will introduce you to the latest cardiovascular

Sunday, Nov. 12 Monday, Nov. 13 Tuesday, Nov. 14 Date/Time Booth Supporter Date/Time Booth Supporter Date/Time Booth Supporter 11:15 a.m.-Noon 1473 Amgen Noon-12:45 p.m. 1473 Janssen Noon-12:45 p.m. 1473 Amgen 2701 Janssen 2701 Aralez 2467 Novo 2467 Sanofi/ Nordisk Regeneron 1:15-2 p.m. 1473 Amgen 12:30-1:15 p.m. 1473 Boehringer 2701 Boehringer Ingelheim Ingelheim 2701 Novartis 2467 Novartis 2467 Amgen 3-3:45 p.m. 2701 Novartis 3:15-4 p.m. 2701 Janssen

This content is provided as information only and does not reflect the opinions of the AHA, nor does AHA review or approve the programming. These events are not part of the official AHA Scientific Sessions 2017 as planned by the AHA Committee on Scientific Sessions Programming.

Data current as of Sept. 5. scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 29 UNOFFICIAL SATELLITE EVENTS

SATURDAY, NOV. 11 MONDAY, NOV. 13 Preventing Pulmonary Embolism and Stroke: A New Era of Enhanced DOAC EVENING MORNING Efficacy and Safety Sponsored by Medscape Education What a Clinician Needs to Know About Getting to the Heart of Type 2 Diabetes Supported by Portola Pharmaceuticals, Inc. Diagnosis and Management of Heart Care: Seeking Better Outcomes in Registration link: http://www.medscape.org/ Disease in Women Patients With Cardiovascular Disease townhall/preventing-pe-and-stroke Sponsored by Washington University Sponsored by Paradigm Medical School of Medicine, Continuing Medical Communications, LLC Providing Quality Care for Patients Education This activity is supported by an educational With Heart Failure Supported by Washington University and grant from Novo Nordisk Inc. This continuing medical education activity is Barnes-Jewish Heart & Vascular Center Registration link: paradigmmc.com/649 provided by Vindico Medical Education. Registration link: http://barnesjewish.org/ This activity is supported by an educational anaheim2017 grant from Novartis Pharmaceuticals EVENING Corporation. Registration link: VindicoCME.com/111317 SUNDAY, NOV. 12 From Clinical Trials to Clinical Practice: Applying Cardiovascular Outcome Trial University of Iowa Reception EVENING Data to Real World T2DM Management Sponsored and supported by: University Sponsored by Creative Educational Concepts of Iowa Hospitals and Clinics Elevated CV Risk in Patients With Supported by AstraZeneca Diabetes: Causes, Implications and Registration link: ceconcepts.com/live/278 New Management Strategies This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by educational grants from Boehringer-Ingelheim Data current as of Sept. 14. While every effort is made to ensure the accuracy of data within this publication, Pharmaceuticals, Inc. and Lilly USA, LLC. the publisher cannot be held responsible Registration link: VindicoCME.com/111217 for errors or omissions.

30 American Heart Association Scientific Sessions 2017 Preview | scientificsessions.org The HEARTBEAT of naheim, California,CALIFORNIA may be best But what you may not know about Southern Heart and Vascular Center and University of known as the home of family- California is that it’s also the site of some of California – Irvine’s Division of Cardiology friendly Disneyland, but there’s the world’s foremost medical breakthroughs. conduct leading-edge research, ranging from A more to Anaheim than the iconic In 1956, for example, the first open-heart basic science and translational investigations to theme park. This Southern California city surgery in the Western U.S. was performed clinical trials, epidemiological studies, health boasts a revitalized, walkable downtown at the University of California, Los Angeles policy and more. featuring excellent entertainment options, (UCLA) Medical Center. In 1992, UCLA’s world-class shopping, from haute couture to Dr. Hillel Laks pioneered the country’s With such an inspiring history of vintage treasures, three professional sports first alternative heart transplant, and was cardiovascular medical breakthroughs and teams (MLB’s Angels, NHL’s Anaheim the first U.S. cardiac surgeon to perform cutting-edge techniques, Anaheim is the Ducks and AFL’s LA KISS), an international bypass surgery on a donor heart prior to perfect location for AHA Scientific Sessions dining scene that rivals any major city in transplantation. 2017, where you will experience the best America, 12 craft breweries sure to entice education, the best new cardiovascular even the most discerning beer lover, and so Southern California also is at the forefront products and the best networking of the year. much more. of cardiovascular research. Multiple facilities We hope you’ll join us in Anaheim! in the area, such as The Orange County Heart Institute and Research Center, Orange County Research Center, St. Joseph Hospital

scientificsessions.org | American Heart Association Scientific Sessions 2017 Preview 31 FREE APPS MAKE TRAVEL EASY Before you leave for AHA Scientific Sessions 2017, download these smartphone apps that will help make planning for Anaheim a breeze.

SeatGuru AHA Mobile LoungeBuddy Displays some App in Meeting Guide Locations of airplane cabin the Air Access to airport lounges charts with Updated status sessions, you can access specs on of flight check in, interaction with for free or a legroom, recline boarding, speakers, links one-time fee ability and take-off and to floor plans, and amenities proximity to landing more offered bathrooms iOS, Android iOS, Android iOS, Android iOS, Android

TripIt Grab AwardWallet Consolidates Search airport Consolidates your travel info Hopper food options frequent flyer (flights, hotels, Flight finder based on gate miles, and hotel rental cars) and and fare locations, pre- and credit card creates one monitor order from the points in one easy-to-access menu, then pick iOS, Android place timed itinerary; up upon arrival iOS, Android includes maps iOS, Android iOS, Android

32 American Heart Association Scientific Sessions 2017 Preview REPATHA® (evolocumab) Table 2. Adverse Reactions Occurring in Greater than 1% of was conducted with evolocumab in infant monkeys. Measurable REPATHA-treated Patients and More Frequently than with Placebo evolocumab serum concentrations were observed in the infant BRIEF SUMMARY OF PRESCRIBING INFORMATION in Pooled 12-Week Studies monkeys at birth at comparable levels to maternal serum, indicating Please see package insert for full Prescribing Information that evolocumab, like other IgG antibodies, crosses the placental barrier. Placebo REPATHA† FDA’s experience with monoclonal antibodies in humans indicates that 1. INDICATIONS AND USAGE (N=1224) (N=2052) they are unlikely to cross the placenta in the first trimester; however, they 1.1 Primary Hyperlipidemia % % are likely to cross the placenta in increasing amounts in the second and third trimester. Consider the benefits and risks of REPATHA and possible REPATHA is indicated as an adjunct to diet and maximally tolerated Nasopharyngitis 3.9 4.0 statin therapy for the treatment of adults with heterozygous familial risks to the fetus before prescribing REPATHA to pregnant women. hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular Back pain 2.2 2.3 In the U.S. general population, the estimated background risk of major disease (CVD), who require additional lowering of low density lipoprotein Upper respiratory tract infection 2.0 2.1 birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. cholesterol (LDL-C). Arthralgia 1.6 1.8 Data 1.2 Homozygous Familial Hypercholesterolemia Nausea 1.2 1.8 Animal Data REPATHA is indicated as an adjunct to diet and other LDL-lowering Fatigue 1.0 1.6 In cynomolgus monkeys, no effects on embryo-fetal or postnatal therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of Muscle spasms 1.2 1.3 development (up to 6 months of age) were observed when evolocumab patients with homozygous familial hypercholesterolemia (HoFH) who was dosed during organogenesis to parturition at 50 mg/kg once every require additional lowering of LDL-C. Urinary tract infection 1.2 1.3 2 weeks by the subcutaneous route at exposures 30- and 12-fold the 1.3 Limitations of Use Cough 0.7 1.2 recommended human doses of 140 mg every 2 weeks and 420 mg once monthly, respectively, based on plasma AUC. No test of humoral immunity The effect of REPATHA on cardiovascular morbidity and mortality has Influenza 1.1 1.2 not been determined. in infant monkeys was conducted with evolocumab. Contusion 0.5 1.0 8.2 Lactation 4. CONTRAINDICATIONS † Risk Summary REPATHA is contraindicated in patients with a history of a serious 140 mg every 2 weeks and 420 mg once monthly combined There is no information regarding the presence of evolocumab in hypersensitivity reaction to REPATHA [see Warnings and Precautions (5.1)]. Adverse Reactions in Eight Pooled Controlled Trials (Seven 12-Week Trials and One 52-Week Trial) human milk, the effects on the breastfed infant, or the effects on milk 5. WARNINGS AND PRECAUTIONS The adverse reactions described below are from a pool of the 52- production. The development and health benefits of breastfeeding should 5.1 Allergic Reactions week trial (Study 2) and seven 12-week trials. The mean and median be considered along with the mother’s clinical need for REPATHA and any potential adverse effects on the breastfed infant from REPATHA or from Hypersensitivity reactions (e.g., rash, urticaria) have been reported exposure durations of REPATHA in this pool of eight trials were 20 weeks and 12 weeks, respectively. the underlying maternal condition. Human IgG is present in human milk, in patients treated with REPATHA, including some that led to but published data suggest that breast milk antibodies do not enter the discontinuation of therapy. If signs or symptoms of serious allergic Local Injection Site Reactions neonatal and infant circulation in substantial amounts. reactions occur, discontinue treatment with REPATHA, treat according Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated 8.4 Pediatric Use to the standard of care, and monitor until signs and symptoms resolve. and placebo-treated patients, respectively. The most common injection The safety and effectiveness of REPATHA in combination with diet and 6. ADVERSE REACTIONS site reactions were erythema, pain, and bruising. The proportions other LDL-C-lowering therapies in adolescents with HoFH who require of patients who discontinued treatment due to local injection site The following adverse reactions are also discussed in other sections additional lowering of LDL-C were established based on data from a reactions in REPATHA-treated patients and placebo-treated patients 12-week, placebo-controlled trial that included 10 adolescents (ages 13 of the label: were 0.1% and 0%, respectively. to 17 years old) with HoFH [see Clinical Studies (14.3)]. In this trial, 7 • Allergic Reactions [see Warnings and Precautions (5.1)] Allergic Reactions adolescents received REPATHA 420 mg subcutaneously once monthly 6.1 Clinical Trials Experience Allergic reactions occurred in 5.1% and 4.7% of REPATHA-treated and 3 adolescents received placebo. The effect of REPATHA on LDL-C and placebo-treated patients, respectively. The most common allergic was generally similar to that observed among adult patients with HoFH. Because clinical trials are conducted under widely varying conditions, Including experience from open-label, uncontrolled studies, a total of 14 adverse reaction rates observed in the clinical trials of a drug cannot be reactions were rash (1.0% versus 0.5% for REPATHA and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus adolescents with HoFH have been treated with REPATHA, with a median directly compared to rates in the clinical trials of another drug and may 0.2%), and urticaria (0.4% versus 0.1%). exposure duration of 9 months. The safety profile of REPATHA in these not reflect the rates observed in clinical practice. Neurocognitive Events adolescents was similar to that described for adult patients with HoFH. Adverse Reactions in Patients with Primary Hyperlipidemia and in In placebo-controlled trials, neurocognitive events were reported in less The safety and effectiveness of REPATHA have not been established in Patients with Heterozygous Familial Hypercholesterolemia than or equal to 0.2% in REPATHA-treated and placebo-treated patients. pediatric patients with HoFH who are younger than 13 years old. REPATHA is not indicated for use in patients without familial hypercho- Low LDL-C Levels The safety and effectiveness of REPATHA have not been established in pediatric patients with primary hyperlipidemia or HeFH. lesterolemia or atherosclerotic CVD [see Indications and Usage (1.1)]. In a pool of placebo- and active-controlled trials, as well as open-label The data described below reflect exposure to REPATHA in 8 placebo- extension studies that followed them, a total of 1988 patients treated 8.5 Geriatric Use controlled trials that included 2651 patients treated with REPATHA, with REPATHA had at least one LDL-C value < 25 mg/dL. Changes to In controlled studies, 1420 patients treated with REPATHA were ≥ 65 background lipid-altering therapy were not made in response to low years old and 171 were ≥ 75 years old. No overall differences in safety including 557 exposed for 6 months and 515 exposed for 1 year (median or effectiveness were observed between these patients and younger treatment duration of 12 weeks). The mean age of the population LDL-C values, and REPATHA dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were patients, and other reported clinical experience has not identified was 57 years, 49% of the population were women, 85% White, differences in responses between the elderly and younger patients, but 6% Black, 8% Asians, and 2% other races. not identified in these trials, the long-term effects of very low levels of LDL-C induced by REPATHA are unknown. greater sensitivity of some older individuals cannot be ruled out. Adverse Reactions in a 52-Week Controlled Trial Musculoskeletal Events 8.6 Renal Impairment No dose adjustment is needed in patients with mild to moderate In a 52-week, double-blind, randomized, placebo-controlled trial Musculoskeletal adverse reactions were reported in 14.3% of REPATHA- (Study 2), 599 patients received 420 mg of REPATHA subcutaneously renal impairment. No data are available in patients with severe renal treated patients and 12.8% of placebo-treated patients. The most common impairment [see Clinical Pharmacology (12.3)]. once monthly [see Clinical Studies (14.1)]. The mean age was 56 years adverse reactions that occurred at a rate greater than placebo were back (range: 22 to 75 years), 23% were older than 65 years, 52% women, pain (3.2% versus 2.9% for REPATHA and placebo, respectively), arthralgia 8.7 Hepatic Impairment 80% White, 8% Black, 6% Asian, and 6% Hispanic. Adverse reactions (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%). No dose adjustment is needed in patients with mild to moderate hepatic impairment (Child-Pugh A or B). No data are available in patients with reported in at least 3% of REPATHA-treated patients, and more Adverse Reactions in Patients with Homozygous Familial Hypercholes- severe hepatic impairment [see Clinical Pharmacology (12.3)]. frequently than in placebo-treated patients in Study 2, are shown in terolemia Table 1. Adverse reactions led to discontinuation of treatment in 2.2% 13. NONCLINICAL TOXICOLOGY In a 12-week, double-blind, randomized, placebo-controlled trial 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility of REPATHA-treated patients and 1% of placebo-treated patients. of 49 patients with HoFH (Study 4), 33 patients received 420 mg of The carcinogenic potential of evolocumab was evaluated in a lifetime The most common adverse reaction that led to REPATHA treatment REPATHA subcutaneously once monthly [see Clinical Studies (14.3)]. study conducted in the hamster at dose levels of 10, 30, and 100 mg/kg discontinuation and occurred at a rate greater than placebo was The mean age was 31 years (range: 13 to 57 years), 49% were women, administered every 2 weeks. There were no evolocumab-related tumors myalgia (0.3% versus 0% for REPATHA and placebo, respectively). 90% White, 4% Asian, and 6% other. The adverse reactions that at the highest dose at systemic exposures up to 38- and 15-fold the occurred in at least two (6.1%) REPATHA-treated patients, and more recommended human doses of 140 mg every 2 weeks and 420 mg once Table 1. Adverse Reactions Occurring in Greater than or Equal to frequently than in placebo-treated patients, included: 3% of REPATHA-treated Patients and More Frequently than with monthly, respectively, based on plasma AUC. The mutagenic potential of • Upper respiratory tract infection (9.1% versus 6.3%) Placebo in Study 2 evolocumab has not been evaluated; however, monoclonal antibodies are • Influenza (9.1% versus 0%) not expected to alter DNA or chromosomes. • Gastroenteritis (6.1% versus 0%) There were no adverse effects on fertility (including estrous cycling, Placebo REPATHA • Nasopharyngitis (6.1% versus 0%) (N=302) (N=599) sperm analysis, mating performance, and embryonic development) % % 6.2 Immunogenicity at the highest dose in a fertility and early embryonic developmental As with all therapeutic proteins, there is potential for immunogenicity. toxicology study in hamsters when evolocumab was subcutaneously Nasopharyngitis 9.6 10.5 The immunogenicity of REPATHA has been evaluated using an administered at 10, 30, and 100 mg/kg every 2 weeks. The highest Upper respiratory tract infection 6.3 9.3 electrochemiluminescent bridging screening immunoassay for the dose tested corresponds to systemic exposures up to 30- and 12-fold detection of binding anti-drug antibodies. For patients whose sera the recommended human doses of 140 mg every 2 weeks and 420 Influenza 6.3 7.5 tested positive in the screening immunoassay, an in vitro biological mg once monthly, respectively, based on plasma AUC. In addition, there Back pain 5.6 6.2 assay was performed to detect neutralizing antibodies. were no adverse evolocumab-related effects on surrogate markers of fertility (reproductive organ histopathology, menstrual cycling, or sperm Injection site reactions† 5.0 5.7 In a pool of placebo- and active-controlled clinical trials, 0.1% of patients treated with at least one dose of REPATHA tested positive for parameters) in a 6-month chronic toxicology study in sexually mature Cough 3.6 4.5 binding antibody development. Patients whose sera tested positive for monkeys subcutaneously administered evolocumab at 3, 30, and 300 Urinary tract infection 3.6 4.5 binding antibodies were further evaluated for neutralizing antibodies; mg/kg once weekly. The highest dose tested corresponds to 744- and none of the patients tested positive for neutralizing antibodies. 300-fold the recommended human doses of 140 mg every 2 weeks and Sinusitis 3.0 4.2 There was no evidence that the presence of anti-drug binding 420 mg once monthly, respectively, based on plasma AUC. Headache 3.6 4.0 antibodies impacted the pharmacokinetic profile, clinical response, 13.2 Animal Toxicology and/or Pharmacology During a 3-month toxicology study of 10 and 100 mg/kg once every 2 Myalgia 3.0 4.0 or safety of REPATHA, but the long-term consequences of continuing REPATHA treatment in the presence of anti-drug binding antibodies are weeks evolocumab in combination with 5 mg/kg once daily rosuvastatin Dizziness 2.6 3.7 unknown. in adult monkeys, there were no effects of evolocumab on the humoral Musculoskeletal pain 3.0 3.3 The detection of antibody formation is highly dependent on the immune response to keyhole limpet hemocyanin (KLH) after 1 to 2 sensitivity and specificity of the assay. Additionally, the observed months exposure. The highest dose tested corresponds to exposures Hypertension 2.3 3.2 incidence of antibody positivity in an assay may be influenced by 54- and 21-fold higher than the recommended human doses of 140 Diarrhea 2.6 3.0 several factors including assay methodology, sample handling, timing mg every 2 weeks and 420 mg once monthly, respectively, based on plasma AUC. Similarly, there were no effects of evolocumab on the Gastroenteritis 2.0 3.0 of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to humoral immune response to KLH (after 3 to 4 months exposure) in a †includes erythema, pain, bruising REPATHA with the incidence of antibodies to other products may be 6-month study in cynomolgus monkeys at dose levels up to 300 mg/kg misleading. once weekly evolocumab corresponding to exposures 744- and 300-fold Adverse Reactions in Seven Pooled 12-Week Controlled Trials greater than the recommended human doses of 140 mg every 2 weeks In seven pooled 12-week, double-blind, randomized, placebo- 8. USE IN SPECIFIC POPULATIONS and 420 mg once monthly, respectively, based on plasma AUC. controlled trials, 993 patients received 140 mg of REPATHA 8.1 Pregnancy Risk Summary This Brief Summary is based on the REPATHA® Prescribing Information subcutaneously every 2 weeks and 1059 patients received 420 mg v3, 07/16 of REPATHA subcutaneously monthly. The mean age was 57 years There are no data available on use of REPATHA in pregnant women to inform a drug-associated risk. In animal reproduction studies, (range: 18 to 80 years), 29% were older than 65 years, 49% women, there were no effects on pregnancy or neonatal/infant development 85% White, 5% Black, 9% Asian, and 5% Hispanic. Adverse reactions when monkeys were subcutaneously administered evolocumab from reported in at least 1% of REPATHA-treated patients, and more organogenesis through parturition at dose exposures up to 12 times frequently than in placebo-treated patients, are shown in Table 2. the exposure at the maximum recommended human dose of 420 mg REPATHA® (evolocumab) every month. In a similar study with another drug in the PCSK9 inhibitor Manufactured by: Amgen Inc. antibody class, humoral immune suppression was observed in infant One Amgen Center Drive monkeys exposed to that drug in utero at all doses. The exposures Thousand Oaks, California 91320-1799 where immune suppression occurred in infant monkeys were greater U.S. License Number 1080 than those expected clinically. No assessment for immune suppression Patent: http://pat.amgen.com/repatha/ © 2016 Amgen Inc. All rights reserved. Not for reproduction. v3 07/16

USA-145-049910 Repatha AHA SS Preview Guide Print Ad_8.375X10.875_Z3.indd 2 8/9/17 11:48 AM PAID ADVERTISEMENT

Learn more about Repatha® at AHA—visit Booth 321

For adults with clinical ASCVD on maximally tolerated statin therapy as an adjunct to diet1 HELP YOUR PATIENTS ESCAPE HIGH LDL-C ADD REPATHA® AND MAXIMIZE LDL-C REDUCTION

Repatha® every 2 weeks + statin delivered UP TO %ADDITIONAL LDL-C 77 REDUCTION compared to placebo + statin1,2

Results from a 12-week study in patients with ASCVD. At week 12, LDL-C was reduced 63% to 77% (mean 71%) with Repatha® 140 mg every 2 weeks + statin more than with placebo + statin. Maximum-dose statins used were atorvastatin 80 mg, rosuvastatin 40 mg, and simvastatin 40 mg.1,2

ASCVD = atherosclerotic cardiovascular disease.

Indication reactions were erythema, pain, and bruising. The proportions of patients who • Repatha® is indicated as an adjunct to diet and maximally tolerated statin discontinued treatment due to local injection site reactions in Repatha®-treated therapy for the treatment of adults with clinical atherosclerotic cardiovascular patients and placebo-treated patients were 0.1% and 0%, respectively. disease (CVD), who require additional lowering of low density lipoprotein Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and cholesterol (LDL-C). placebo-treated patients, respectively. The most common allergic reactions were • The effect of Repatha® on cardiovascular morbidity and mortality has been rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% published. Inclusion of the results in the approved labeling is under versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%). evaluation with the FDA. Neurocognitive events were reported in less than or equal to 0.2% in Repatha®-treated and placebo-treated patients. Important Safety Information • Contraindication: Repatha® is contraindicated in patients with a history of a In a pool of placebo- and active-controlled trials, as well as open-label extension ® serious hypersensitivity reaction to Repatha®. studies that followed them, a total of 1,988 patients treated with Repatha had at least one LDL-C value < 25 mg/dL. Changes to background lipid-altering • Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been ® ® therapy were not made in response to low LDL-C values, and Repatha dosing reported in patients treated with Repatha , including some that led to was not modified or interrupted on this basis. Although adverse consequences of discontinuation of therapy. If signs or symptoms of serious allergic reactions ® very low LDL-C were not identified in these trials, the long-term effects of very occur, discontinue treatment with Repatha , treat according to the standard of low levels of LDL-C induced by Repatha® are unknown. care, and monitor until signs and symptoms resolve. Musculoskeletal adverse reactions were reported in 14.3% of Repatha®-treated • Adverse reactions: The most common adverse reactions (> 5% of ® patients and 12.8% of placebo-treated patients. The most common adverse Repatha -treated patients and more common than placebo) were: reactions that occurred at a rate greater than placebo were back pain (3.2% nasopharyngitis, upper respiratory tract infection, influenza, back pain, and versus 2.9% for Repatha® and placebo, respectively), arthralgia (2.3% versus injection site reactions. 2.2%), and myalgia (2.0% versus 1.8%). In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% ® ® • Immunogenicity: Repatha is a human monoclonal antibody. As with all of Repatha -treated patients and 1% of placebo-treated patients. The most therapeutic proteins, there is a potential for immunogenicity with Repatha®. common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Please see Brief Summary of full Prescribing Information ® Repatha and placebo, respectively). on adjacent page. • Adverse reactions from a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated References: 1. Repatha® (evolocumab) Prescribing Information, Amgen. 2. Data on file, and placebo-treated patients, respectively. The most common injection site Amgen; 2015.

USA-145-049910 Repatha AHA SS Preview Guide Print Ad_8.375X10.875_Z3.indd 1 8/9/17 11:48 AM